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Abstract: 
 Postpartum female rats immediately respond to biological or foster 
offspring with the display of maternal behavior. In contrast, females that are 
hysterectomized and ovariectomized on day 15 of pregnancy (15HO) and 
presented with pups 48 hours later show maternal behavior after 2-3 days of pup 
exposure. The natural onset of maternal behavior in postpartum females is 
mediated, in part, by the rise in estradiol just prior to birth. When 15HO rats are 
administered estradiol benzoate (EB) at the time of HO surgery, 48 hours prior to 
pup presentation, they show an almost immediate onset of maternal behavior. 
Presumably, EB administration functions to prime neural circuits which regulate 
maternal behavior such that these circuits respond to pup presentation with 
increased maternal responsiveness. Two important neural regions which have 
been shown to interact in order to promote responsiveness toward infant stimuli 
are the medial preoptic area (MPOA) and the nucleus accumbens (NA). The 
following series of studies were undertaken to examine how dopamine (DA) 
activity within these two important neural sites substitutes for the facilitatory 
effects of chronic (48 hours) EB stimulation of maternal behavior in 15HO rats. 
Study 1 investigates whether, in the absence of EB treatment, microinjection of  
dopamine receptor agonists into either NA or MPOA at the time of pup 
presentation stimulate maternal behavior in 15HO rats. Study 2 examines the 
underlying mechanism by which DA receptor stimulation of NA promotes the 
onset of maternal behavior in 15HO rats. Finally, Study 3 examines the 
relationship between DA receptor stimulation and estradiol stimulation in the 
facilitation of maternal responsiveness in 15HO rats.
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I. Introduction: 
 The goal of my research has been to uncover aspects of the neural circuitry 
which regulates maternal motivation in rats, or the change in responsiveness 
toward pup stimuli which occurs naturally at birth. In particular, maternal behavior 
in rats is an excellent model with which to examine neural regulation of 
motivation, because female rats display a dramatic change in responsiveness 
toward infant stimuli, such that a female rat who is unresponsive to infant stimuli 
prior to birth rapidly approaches and responds to infant stimuli at the time of birth. 
Importantly, aside from being an excellent model with which to understand 
motivation in general, research on maternal behavior in rats provides relevant 
implications for our understanding of human maternal behavior as well. There 
are, of course, differences between species, but because maternal motivation is 
a defining characteristic of all mammals, it is likely that a core neural circuit which 
regulates maternal behavior has been conserved across species (Numan and 
Insel, 2003). In this context, individual variation in maternal motivation across 
species might be explained by the extent to which hormonal, genetic, and 
experiential factors impact this core neural circuit. Finally, note that this core 
neural circuit does not include the regulation of species-specific behavioral 
responses toward infants. For example, humans do not carry infants in their 
mouths the way that rodents do, and therefore the neural mechanisms underlying 
the specific behaviors which vary between species are not addressed here, 
instead the scope of my research has been to understand the core neural circuit 
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which regulates the change in responsiveness or maternal motivation which is 
expressed across species.
Maternal behaviors, like all reproductive behaviors, can be dichotomized 
into appetitive and consummatory components (Ball and Balthazart, 2008). The 
initial phase of attraction and pursuit, termed the appetitive phase, is comprised 
of behaviors which bring the organism into contact with the goal stimulus, and is 
followed by the final phase of consummation, or the consummatory phase, in 
which the organism interacts with the acquired stimulus. Because the appetitive 
components of reproductive behavior are variable behavioral responses which 
depend upon the different environmental constraints or obstacles the organism 
must overcome to gain access to the goal stimulus, higher cognitive processes 
are probably recruited to mediate appetitive reproductive behaviors. In contrast, 
since the consummatory components of reproductive behavior are predictable, 
invariant, and usually reflexive in nature, they are likely mediated in large part by 
brainstem and spinal cord mechanisms.
Rat pups are born altricial, which means they have limited sensory and 
motor capabilities and are not able to regulate their body temperature or urinate 
and defecate on their own; therefore, infants are entirely dependent on maternal 
behaviors for their survival. After giving birth, female rats naturally respond to 
their infants by building a nest and crouching over the pups to keep them warm. 
Females lick and groom pups, which aids in urination and defecation, and feed 
them by adopting nursing postures over pups allowing them to suckle and 
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receive milk. Should pups become displaced, or should the female need to move 
her nest, she picks the pups up in her mouth and carries them to the nest. This 
transport behavior is referred to as retrieval behavior. 
Typically, approach behaviors which help the female gain access to her 
pups can be conceptualized as the appetitive components of maternal behavior, 
and this would include retrieval behavior, during which the female initiates 
contact with her pups (Numan and Insel, 2003). Note that some question exists 
as to whether retrieval behavior, which also requires a stereotypical mouthing 
and picking up of the pups, can also be considered a consummatory component 
of maternal behavior. However, there are two important aspects of retrieval 
behavior which classify it as an appetitive behavior. First, retrieval behavior is 
variable and dependent upon complex cognitive processes. In order to retrieve 
pups to the nest, the female must find the pups, recall the location of her nest, 
remember where she has searched for pups and where she has yet to search, 
determine which route to take to get to her nest, and determine if she has 
collected all of her pups at the nest or if she must continue to search for her 
pups.  Second, if one views nursing behavior as the goal of maternal interaction, 
then retrieval behavior, which brings the pups to the nest so they can be nursed, 
should also be considered an appetitive component of maternal behavior. 
Furthermore, because the goal of our laboratory has been to examine the brain 
circuits which regulate mother-initiated maternal responses, retrieval behavior is 
an important dependent variable in many of our studies. Finally, by studying the 
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neural mechanisms regulating the transition from pup avoidance to maternal care 
(onset of maternal behavior) we should be tapping into basic appetitive 
motivational mechanisms.
While postpartum female rats display maternal behaviors in the presence 
of offspring (including offspring that are not biologically related), virgin female rats 
do not display these behaviors when presented with pups, rather they avoid them 
(Numan and Insel, 2003). However, if nulliparous female rats are continuously 
cohabitated with freshly nourished pups from a donor mother each day, after 
about 8 days they will come to display full maternal behavior almost 
indistinguishable from that of a lactating female (Rosenblatt, 1967). This process 
in which repeated exposure to pups induces maternal behavior in virgin female 
rats is called sensitization, and the number of days required before the female 
exhibits responsiveness is referred to as her sensitization latency. The finding 
that virgin female rats can be induced to show maternal behavior after a period of 
pup sensitization indicates that the hormonal events of pregnancy and parturition 
are not necessary for maternal responsiveness to occur; instead they reduce the 
amount of pup exposure required for maternal behavior to be initiated (Numan, 
2006).
Exposure to the hormonal events of pregnancy, which lasts 22 or 23 days, 
facilitates the rapid onset of maternal behavior (Numan and Insel, 2003). First, 
cervical stimulation during mating initiates a twice-daily pattern of prolactin 
release from the anterior pituitary (for approximately 9-10 days after mating) 
4
which functions to rescue the corpora lutea from degradation, and as a result, 
steadily increase progesterone (P) levels during the first part of pregnancy 
(Erskine, 1995). After day 10, a shift takes place such that placental lactogens 
support the luteal secretion of P that is necessary for the continuation of 
pregnancy. During early pregnancy, P prepares the uterine endometrium for 
implantation of the blastocysts and once implanted, it maintains a uterine 
environment that promotes growth of the embryos and prevents an early 
expulsion of the fetuses (Turner, 1966; Zakar and Hertelendy, 2007). While rising 
levels of P promote the maintenance of pregnancy, the decline of P beginning in 
mid-pregnancy initiates a shift in hormonal events that eventually regulates the 
timing of labor. Increasing levels of estradiol (E) secreted from the ovary prepare 
the uterine endometrium for labor by promoting rhythmic contractility of the 
uterus, and the sharp decline in P just before birth removes the inhibitory tone on 
the uterine muscles and allows them to respond to the surge in oxytocin (OT) 
from the posterior pituitary that induces uterine contraction and labor. Finally, as 
parturition approaches, the hormonal shift from P dominance to E dominance, in 
combination with peripherally released OT and prolactin functions to prepare the 
uterus for birth of the fetuses, while E in combination with centrally released OT 
and prolactin primes neural circuits to respond to infant stimuli at birth (Bridges et 
al., 1990; Numan and Insel, 2003; Pedersen et al., 1994). 
Although the pregnant rat is exposed to circulating levels of pregnancy 
hormones, responsiveness toward pup stimuli first emerges in the final hours 
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prior to parturition (Mayer and Rosenblatt, 1984). Therefore the hormonal events 
which occur at this time probably play a role in stimulating the onset of maternal 
behavior. The early work of Terkel and Rosenblatt (1968, 1972) empirically 
explored this idea and reported that factors circulating in the blood at the time of 
birth and just after birth were responsible for initiating maternal responsiveness. 
They found that blood transfused from a maternal female rat (taken within 24-48 
hours of giving birth) to a virgin female rat produced significantly shortened 
sensitization latencies in the virgin rat. Research conducted during the next 
several decades has supported the idea that the precipitous decline in P in 
combination with the rise in E and lactogens, which occurs during the final 48 
hours of pregnancy, is responsible for the immediate maternal responsiveness of 
parturient females at birth (Numan, 1988). 
First, artificial termination of pregnancy by hysterectomy (H; removal of 
uterus and fetuses) during the latter half of pregnancy (after a period of P 
secretion) produces a decline in P levels due to removal of the influence of 
placental lactogens; the drop in P levels combined with rising E secretion (the 
natural rise in E during late pregnancy is potentiated by removal of P) is strikingly 
similar to the hormonal profile which occurs just prior to parturition, and this 
preparation produces an immediate onset of maternal behavior when pups are 
presented 48 hours after surgery (Rosenblatt and Siegel, 1975). Note that if pups 
are presented before P has declined (Bridges et al., 1978; Siegel and Rosenblatt, 
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1978) or if P is maintained (Doerr et al., 1981; Numan, 1978; Siegel and 
Rosenblatt, 1975b, 1978) the onset of maternal behavior is delayed. 
Second, the presence of E is equally as important as the decline in P for 
the stimulation of maternal behavior because ovariectomy (O) at the time of H 
(which would produce a decline in E as well as P) prevents the full facilitatory 
effects of H on the onset of maternal behavior (Siegel and Rosenblatt, 1975a). 
Female rats that are hysterectomized and ovariectomized (HO) on day 15 of 
pregnancy (15HO) require about 3 days of exposure to pups prior to showing 
maternal behavior (significantly more than the immediate responsiveness of the 
15H animal). Importantly, the injection of estradiol benzoate (EB) at the time of 
HO can reinstate immediate onset in 15HO rats. Note that while the 3 day 
latency of 15HO females is significantly longer than that of 15HO +EB treated 
females, it is also significantly shorter than the sensitization latency of a virgin 
female (about 7-8 days). Therefore, 15HO females might be regarded as 
receiving a sub-optimal or partial hormone priming due to the partial facilitation of 
this preparation on the onset of maternal behavior. 
Third, nulliparous virgin female rats administered a hormone schedule 
which mirrors the latter half of pregnancy, show a facilitated onset of maternal 
behavior. Moltz, Lubin, Leon, and Numan (1970) were the first to examine 
sensitization latencies of ovariectomized virgin female rats given the following 
hormone injection schedule: EB for days 1-11, P for days 6-9, and prolactin on 
days 9 and 10. On the morning of day 10 females were presented with pups and 
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tested for maternal behavior. Females receiving this schedule of injections 
showed about a 2 day sensitization latency. Note that while this latency is not as 
short as the 0-1 day latency in 15H or 15HO + EB females, it is still significantly 
shorter than the latency of a virgin female rat (about 7-8 days). Also note P 
injection on day 10 prevented a facilitated onset of maternal behavior. Bridges 
(1984) went on to examine whether virgin females administered physiological 
doses of E and P needed exogenous prolactin in order to show a facilitated onset 
of maternal behavior. Results indicated that E and P injection alone are sufficient 
to induce maternal behavior. However prolactin is still involved since E stimulates 
the release of prolactin from the pituitary gland and because E and P injections 
do not stimulate maternal behavior in hypophysectomized rats (Bridges and 
Dunckel, 1987).  
The primary conclusion of the pregnancy termination and virgin 
sensitization studies presented above, is that high E and lactogens 
superimposed on a backdrop of P withdrawal facilitate maternal behavior. The 
role of P decline in the facilitation of maternal behavior is related to its ability to 
lower the threshold of E stimulation necessary to produce a behavioral effect 
(Doerr et al., 1981; Siegel and Rosenblatt, 1975a, 1975b 1978); other studies 
have shown that E alone can stimulate maternal behavior, but only with much 
higher, supraphysiological doses (Bridges, 1984).
One neural site where hormones act to promote the onset of maternal 
behavior is the medial preoptic area of the hypothalamus (MPOA). The MPOA 
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contains estrogen receptors (Shughure et al., 1997), prolactin receptors 
(Bakowksa and Morrell, 1997), progesterone receptors (Numan et al., 1999), and 
oxytocin receptors (Champagne et al.,  2001). Using the pregnancy termination 
model, Numan, Rosenblatt, and Komisaruk (1977) showed that 15HO female 
rats that normally required 2-3 days of pup exposure to induce maternal behavior 
would show maternal behavior on the first day of pup exposure when implanted 
with EB directly into MPOA, suggesting that the MPOA is at least one neural site 
where the rise in E at the end of pregnancy acts to promote the onset of maternal 
behavior.
Not surprisingly, a large body of evidence indicates that damage to the 
MPOA impairs maternal behavior (Numan and Insel, 2003). Interference with 
MPOA activity either with lesions (both electrical and excitotoxic) or 
pharmacological depression severely disrupts maternal behavior in sensitized 
virgin, parturient, and postpartum females (Arrati et al., 2006; Fleming et al., 
1983; Gray and Brooks, 1984; Jacobson et al., 1980; Kalinchev et al., 2000; Lee 
et al.,  2000; Numan, 1974; Numan and Callahan, 1980; Numan et al., 1988; 
Numan et al., 1977). Additionally, knife cuts which sever the lateral connections 
of MPOA produce similar deficits in maternal responding, suggesting the 
importance of lateral MPOA efferents in the regulation of maternal behavior 
(Numan, 1974;Numan and Callahan, 1980; Terkel et al., 1979). While MPOA 
lesions have been shown to affect all aspects of maternal behavior, note that the 
active components such as retrieval and nest building show the most severe 
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impairments, as first pointed out in Terkel et al. (1979). Based on the extensive 
evidence that MPOA damage disrupts maternal behavior and hormonal 
stimulation of MPOA potentiates maternal behavior, the MPOA is considered a 
central, critical site for the regulation of maternal behavior (Numan, 2006). 
How does the MPOA regulate maternal behavior? While the hormonal 
events of parturition can induce maternal behavior, this hormonal profile is 
relatively short lived. Evidence indicates, however, that once maternal behavior is 
initiated at parturition, its maintenance during the postpartum period is 
independent of hormonal control (Numan and Insel, 2003). The interaction 
between hormones and afferent input from pups within MPOA during the onset of 
maternal behavior might modify MPOA neurons such that they are responsive to 
pup related stimuli even in the absence of continued hormonal stimulation. From 
a molecular perspective, one way steroid hormones, like E and P, exert their 
effects is by altering gene expression. Long term changes in gene expression 
can change the phenotype of neurons, altering the type of stimuli a particular 
neuron responds to as well as the type of response elicited (Sheng and 
Greenberg, 1990). Therefore, hormones might be involved in modifying MPOA 
neurons such that they are responsive to pup inputs even after the hormonal 
events of birth wane.  
The most common description of the mechanism by which steroid 
hormones [such as estradiol (E), progesterone (P), and testosterone (T)] alter 
cellular function is via their slow acting, but long lasting effects on gene 
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transcription (Beato and Klug, 2000). Their lipid-like structure enables them to 
permeate the plasma membrane of cells and diffuse into the nucleus where, 
once bound by their protein receptor, they form a complex that interacts with 
steroid responsive DNA sequences to activate or repress the expression of 
particular genes. Steroid receptors can also be found in the cytoplasm, in which 
case the bound steroid receptor complex translocates to the nucleus to exert its 
effects. A classic example of this mechanism is the induction of progesterone 
receptors (PR) by the steroid E (Kraus et al., 1994). In this case, the ligand 
bound estrogen receptor (ER) binds to an estrogen response element (ERE) in 
the promoter region of the PR gene where it initiates transcription and, after 
several hours, results in a high density of PR in the cell. 
Steroid hormones are also capable of initiating the transcription of genes 
which do not contain steroid responsive elements. This newly recognized 
mechanism involves both recently identified steroid membrane receptors as well 
as intracellular receptors (Beato and Klug, 2000; Bishop and Stormshak, 2008; 
Bjornstrom and Sjoberg, 2005; Foradori et al.,  2008; Kelly and Levin, 2001; 
Mhyre and Dorsa, 2006; Toran-Allerand, 2004; Vasudevan and Pfaff, 2007, 
2008). For example, while it has been documented that ovariectomized female 
rats treated with E show increased expression of the neurotransmitter 
neurotensin in the MPOA which is indicative of increased transcription of the 
neurotensin gene, the neurotensin gene clearly lacks an ERE (Mhyre and Dorsa, 
2006). A series of experiments revealed that E administration increases the 
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expression of neurotensin by affecting a protein which is capable of initiating 
transcription of the neurotensin gene. Specifically, E stimulates an intracellular 
signaling cascade which ultimately phosphorylates or activates the cyclic AMP 
response element binding protein (CREB), a protein which binds to a calcium or 
cyclic AMP response element (CRE) in the promoter region of the neurotensin 
gene (Mhyre and Dorsa, 2006). Importantly, because many genes have CRE in 
their promoter regions, and because the phosphorylation of CREB is typically 
mediated by intracellular signaling cascades initiated by neurotransmitter binding 
at the cell membrane, this finding revealed a myriad of possible genes which 
steroid hormones might influence, and suggested a common mechanism by 
which steroids and neurotransmitters might exert their effects.   
In addition to altering gene transcription at CRE sites, note that rapid 
phosphorylation of CREB indicates that steroid hormones activate intracellular 
signaling cascades that can also produce rapid cellular changes. This last point 
calls attention to a second important alteration in our conceptualization of steroid 
hormone action. Whereas it has generally been thought that hormones produce 
their effects in hours or even days, it is now clear that hormone binding can 
induce cellular changes measurable in just minutes. For example, E is capable of 
increasing CREB phosphorylation in minutes (Abraham et al., 2004). This 
example suggests that cytoplasmic proteins (rather than nuclear proteins) may 
also be phosphorylated within minutes of E activation of signaling cascades, and 
therefore promptly modify cellular function. 
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In summary, two important nonclassical aspects of steroid function should 
be noted: (1) steroids can influence the transcription of genes which do not have 
steroid responsive elements via a number of mechanisms, but importantly, (2) 
one of these mechanisms involves signaling cascades initiated at the cell 
membrane which can rapidly alter cell function in response to extracellular 
signals. Finally, while steroids produce their effects via both genomic and 
nongenomic mechanisms, convergence between these pathways is a key 
component of steroid action and enables hormones to influence the same 
behavioral and cellular endpoints through more than one route.
If the hormonal events of pregnancy and parturition, particularly the rise in 
E, alter MPOA neurons to increase maternal responsiveness, what changes in 
gene transcription mediate this effect? One family of genes that can be activated 
by the hormonal events of pregnancy termination is referred to as the immediate 
early genes (IEGs; Sheehan and Numan, 2002). When a neuron has been 
stimulated (for example, by a hormone, neurotransmitter, or neuromodulator) 
IEGs are transcribed within minutes (Sheng and Greenberg, 1990). Generally, 
IEGs play a regulatory role in the neuron, influencing how extracellular events 
are translated into genomic activation. IEGs accomplish this by encoding protein 
transcription factors which bind to DNA and activate or repress the transcription 
of later responding genes (these later responding genes would serve more 
specific roles, ie. affect neurotransmitter content or receptor expression). 
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Because IEGs are transcribed very quickly in response to numerous 
extracellular events, their protein products can be easily visualized using 
immunocytochemical techniques. The most commonly visualized member of the 
IEG family is the protein Fos. The Fos protein can be localized by treating tissue 
from a sacrificed animal with a labeled antibody raised against the Fos protein. 
The presence of Fos immunoreactivity (Fos-IR) has proven a reliable marker for 
neuronal responses during maternal behavior. Mice with a mutation of the fos B 
gene show a complete abolishment of maternal behavior, while these females 
show surprisingly normal behavior in other hypothalamically controlled systems 
(body temperature, food intake, sexual behavior; Brown et al., 1996; also see 
Kuroda et al., 2008). 
In support of the idea that hormones are modifying the phenotype of 
MPOA neurons with Fos expression being one of the markers for those changes, 
the hormonal events of pregnancy termination induce Fos expression in MPOA 
neurons (Sheehan and Numan, 2002). The MPOA also shows increased Fos–IR 
while a female rat is interacting with her pups during the postpartum period 
(Fleming et al., 1994b; Lonstein and DeVries, 2000; Numan and Numan, 1994, 
1995; Stack and Numan, 2000) and while she is searching an environment that 
previously contained pups (Mattson and Morrell, 2005). This pup induced Fos 
expression can be separated from pregnancy hormone- induced Fos expression, 
as it occurs in sensitized virgin female rats but not in virgins who have been 
exposed to pups but who have not yet sensitized (Numan and Numan, 1994). 
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The fact that initially hormone stimulation and subsequently pup stimulation can 
induce Fos expression in the MPOA suggests that Fos expression in MPOA may 
alter the responsiveness of MPOA neurons to pup inputs. Although Fos may be 
involved in modifying the phenotype of MPOA neurons so that they become 
responsive to inputs derived from pup stimuli, just which late-responding genes 
are activated by Fos to produce such effects is not known. In addition, hormonal 
events and pup stimuli are likely to influence many other genetic and cellular 
processes in order to promote maternal behavior. 
What types of neurons in the MPOA express Fos during mother-pup 
interactions and where do these neurons project in order to influence maternal 
behavior? Double labeling immunohistochemical procedures can be used to 
determine the phenotype of neurons expressing Fos as well as where these 
neurons terminate. Lonstein, Greco, De Vries, Stern, and Blaustein (2000) have 
shown that MPOA neurons which express estrogen receptor α (ER α) show Fos 
expression during maternal behavior. MPOA has a strong projection to the 
ventral tegmental area (VTA: Numan and Numan, 1996), and neurons that bind E 
in the MPOA terminate in the VTA (Farbach and Pfaff, 1986). MPOA neurons 
which are activated by mother-pup interaction (as indicated by Fos expression) 
also have a projection to the VTA (Numan and Numan, 1997). While a triple 
labeling study has not been completed, the results strongly suggest that MPOA 
neurons which bind estradiol and show Fos expression during maternal behavior 
terminate in the VTA. The VTA gives rise to ascending dopaminergic fibers which 
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include those which terminate in the nucleus accumbens (NA), known as the 
mesolimbic dopamine (DA) system.  Although the MPOA projects to more than 
one region in order to influence maternal responsiveness, a focus of my research 
has been to understand the interaction between the MPOA and the mesolimbic 
DA system in the regulation of proactive responsiveness toward pups. 
Importantly, interference with the release of DA into the NA produces 
similar deficits in maternal behavior as MPOA lesions, suggesting that MPOA 
efferents might regulate the appetitive components of maternal behavior via 
activation of the mesolimbic DA system. Electrolytic lesions of the VTA  (Numan 
and Smith, 1984) or pharmacological depression of the VTA (Numan et al., in 
press) disrupt maternal behavior, and microinjection of 6-hydroxydopamine, a 
toxin which is taken up by DA neurons and selectively destroys them, produces 
the same effect when injected into VTA (Hansen et al., 1991a,b). Reversible, 
pharmacological antagonism of DA in NA, which allows more specificity and 
causes less damage, also impairs maternal behavior (Keer and Stern, 1999; 
Silva et al., 2003; Numan et al., 2005a). 
Generally speaking, the mesolimbic DA system is widely believed to 
regulate behavioral responsiveness toward many biologically significant stimuli 
through its projection to the NA  (Numan, 2006).  The NA receives most of its 
other inputs from the limbic system (hippocampus, prefrontal cortex, and 
amygdala; Pennartz et al., 1994) and it is comprised almost entirely of medium 
spiny GABAergic output neurons (MSN) which have a major                    
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projection to a basal ganglia motor nucleus called the ventral pallidum (VP; 
Pennartz et al., 1994; Zahm and Heimer, 1993; Zhou et al., 2003). The NA-VP 
circuit has been called a limbic-motor interface (Mogenson, 1987), as it is the 
pathway by which sensory inputs which have first been processed by the limbic 
system can influence the motor system and direct behavior. DAergic inputs to 
NA function to increase the responsiveness of the NA-VP circuit to limbic inputs 
(Heidenreich et al., 1995). The mesolimbic DA system has been referred to as a 
nonspecific motivational system because DA action at the level of NA increases 
an organisms responsiveness to a wide variety of biologically significant stimuli 
(Numan, 2006). 
Gordon Mogenson (1987) proposed that DA release into NA functions to 
depress the responsiveness of MSN output neurons which project to the VP. 
Therefore DA produces its behavioral effects on motor activity by releasing the 
VP from NA inhibition. Mogenson proposed this model on the basis of his 
straightforward findings: increased DA release into NA (either by stimulation of 
VTA or by exogenous administration) increased locomotor activity in an open 
field, and this effect could be blocked by pharmacological depression of the VP. 
Mogenson concluded that while NA to VP connections are important for 
locomotion, because the NA to VP projection is GABAergic and increasing 
GABA in VP resulted in depression of motor activity, DA must act to increase 
motor activity by reducing NA GABA output to VP.
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This model has been extended by Numan (1988, 2006) with respect to 
maternal behavior. Infant stimuli can presumably gain access to the NA-VP circuit 
through limbic afferents originating in the prefrontal cortex and the amygdala, 
which are glutamatergic and terminate in both the NA and VP (Charara and 
Grace, 2003; Maeda et al., 2004; Maslowski-Cobuzzi et al., 1994; Petrovich et 
al., 1996; Sesack et al., 1989; see Figure I). While infant stimuli are potentially 
capable of exciting this circuit, they are not likely to elicit motor responsiveness 
without DAergic intervention because excitation of NA GABAergic output neurons 
results in inhibition of VP, preventing the VP from processing excitatory pup 
inputs and stimulating motor output. Therefore, DA action on NA, by depressing 
NA responsiveness to limbic inputs, would allow VP to respond to such inputs.
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Figure 2. 
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Figure I. Schematic of the mesolimbic dopamine (DA) system: A. The nucleus 
accumbens (NA) and ventral pallidum (VP) receive excitatory inputs from the 
basolateral amygdala (BLA; triangles refer to glutamate release). In the absence 
of DA release, BLA projections to the NA-VP circuit do not result in behavioral 
reactivity because the projection from NA to VP is inhibitory. Therefore excitation 
of NA cancels out excitation of VP. B. MPOA activates the VTA and induces DA 
release into NA (circles refer to DA). In the presence of DA input from the VTA, 
the impact of excitatory input to NA is dampened and inhibitory output to VP is 
silenced, allowing excitatory BLA input to the VP to result in behavioral activation. 
(Adapted from Numan, 2006).
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In contrast, other labs contend that DA action on NA output stimulates 
behavioral reactivity by increasing NA responsiveness to cortical and limbic 
afferents (Nicola et al., 2000). NA output, therefore, is critical. More specifically,  
this view proposes that DA release into the NA attenuates weak excitatory inputs 
from PFC, amygdala, hippocampus, while potentiating strong excitatory inputs. In 
this way, NA output is driven by strong inputs. DA activity in the NA can therefore 
be viewed as a modulator that increases the likelihood that strong inputs will 
evoke a response and reduces the likelihood that weak inputs will evoke a 
response, which has often been identified as increasing the signal to noise ratio 
(Horvitz, 2002; Nicola et al, 2000). 
 If the latter hypothesis is applied to the maternal behavior, two 
assumptions can be made:(1) NA activity and therefore output would be critical 
for proactive aspects of maternal behavior; therefore lesions of the NA or 
pharmacological depressions of NA activity would have a disruptive effect on 
maternal responsiveness, and (2) VP activity is not critical, rather inhibition of VP 
activity would be expected because NA output is inhibitory. In contrast, the 
Mogenson (1987) hypothesis would suggest the opposite, that VP depression 
rather than NA depression would disrupt maternal behavior. 
 Recent data from our lab  are consistent with Mogenson’s view (Numan et 
al, 2005b). For example, NA lesions do not disrupt the onset (Lee et al., 1999; Li 
and Fleming, 2003; Numan et al., 2005b) or the maintenance of maternal 
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behavior (Numan et al., 2005b), suggesting that while DA receptor action in NA is 
critical for maternal behavior to occur (Keer and Stern, 1999; Numan et al., 
2005a), NA activity is not. On the other hand, interference with VP activity, either 
with excitotoxic lesions or temporary inactivation, disrupts the display of maternal 
behavior (Numan et al., 2005b). 
 Given that the mesolimbic DA projection from the VTA to NA is important 
for maternal behavior, what activates this system so that is can be utilized to 
control maternal responsiveness? In addition to the anatomical evidence already 
described, neurobehavioral evidence suggests the importance of MPOA 
activation: using an asymmetrical design, Numan and Smith (1984) 
demonstrated that unilateral MPOA lesions severely disrupt maternal 
responsiveness (particularly retrieving) when paired with a VTA lesion on the 
opposite side of the brain. When a unilateral MPOA lesion is paired with a VTA 
lesion on the same side of the brain maternal behavior remains intact. Therefore, 
not only is VTA activity critical for maternal behavior, but MPOA inputs to VTA 
appear necessary for mother-initiated responsiveness toward pups. 
In further support of the importance of MPOA to NA-VP connectivity in the 
regulation of maternal behavior, Numan et al. (2005b) found that unilateral 
lesions of MPOA paired with contralateral depression of VP resulted in severe 
deficits in maternal responding, while disruption of this system unilaterally did 
not. In light of the fact that unilateral MPOA lesions alone do not disrupt maternal 
behavior, this finding suggests that MPOA and VP are functionally linked. From 
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this data, along with anatomical findings that MPOA neurons which express Fos 
during maternal behavior project to VTA and MPOA neurons which bind estradiol 
project to VTA, the following model is proposed: when the MPOA has been 
properly primed with hormones, pup stimuli activate MPOA neurons which project 
to VTA DA neurons. DA release into NA disinhibits the VP, allowing VP to respond 
to pup inputs so that maternal behavior can occur (Numan, 2006; Numan et al., 
2005a,b). 
The above findings provide support for the idea that MPOA output is 
necessary for VP activation of maternal behavior. There is other evidence that 
also shows that MPOA activity is necessary for NA function during maternal 
behavior. Both MPOA and NA show increased Fos expression during maternal 
behavior (Stack et al., 2002). Unilateral MPOA lesions (which do not disrupt 
maternal behavior) reduce maternal behavior induced Fos expression in the NA 
on the same side of the brain as the MPOA lesion. Fos expression induced by 
maternal behavior in the contralateral NA, which would presumably still be 
receiving the presumed MPOA inputs, remains intact. 
Note that while the presence of Fos is usually interpreted to mean that a 
cell has been active, activation does not necessarily equate with Fos expression 
(Hoffman and Lyo, 2002). In our model, for example, Fos expression in NA might 
be induced as a result of an intracellular signaling cascade initiated by DA 
receptor activation. For example, DA exerts its effects by binding to one of the 
five characterized DA receptor subtypes (Missale et al., 1998). These five 
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receptors have been classified into two receptor subtype families: D1-like (D1 
and D5) and D-2 like (D2, D3, and D4). All DA receptors are G-protein coupled, 
which means that when DA binds to its receptor, rather than directly inducing 
changes in membrane electrical conductance, it activates a G protein coupled to 
the intracellular component of the receptor. This G-protein initiates a second 
messenger cascade which results in intracellular signaling, activation of protein 
kinases which phosphorylate proteins, and genomic activation, all which can 
modulate the way the neuron responds to straightforward excitatory and 
inhibitory inputs. In other words, one function of this signaling cascade is to 
modulate a neuron’s responsiveness to other neurochemical inputs which directly 
affect conductance. Therefore, DA receptor activation could result in both a 
depression in neural responsiveness as well as induction of Fos. Specifically, DA 
action on D1 receptors has been found to depress NA responses to limbic inputs 
(Charara and Grace, 2003; Harvey and Lacey, 1997; O’Donnell et al., 1999; 
Pennartz et al., 1994), and induce Fos expression in NA (Blandini et al,, 2003; 
Robertson and Jian, 1995). There is also evidence DA action on D1 receptors 
can induce Fos in striatal neurons which are being depressed (Berretta et al., 
1992). The downstream intracellular signaling cascades initiated by DA D1 
stimulation can also result in the neuron being less responsive to glutamatergic 
inputs in the future (Hara and Pickel, 2005; Pei et al., 2004). With respect to 
these two mechanisms: DA-D1 induced decreases in NA responsiveness and 
DA-D1 induced activation of Fos, at present it is not clear how they might be 
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related. It is tempting to speculate that Fos induction might activate genes which 
result in the synthesis of proteins which cause a long term decrease in the 
responsiveness of NA neurons to limbic inputs. 
Although no one has shown that DA inhibits NA neurons during maternal 
behavior, several studies have shown that NA neurons are inhibited during 
increased behavioral reactivity toward other biologically important stimuli, like 
food (Carelli et al., 2000; Taha and Fields, 2006). In support of the idea that 
neural inhibition of NA neurons during goal-directed behavior is related to DA 
action at the level of the NA, Cheer et al. (2007) have shown that phasic changes 
in DA release, on the scale of milliseconds, during operant responding for 
intracranial self stimulation, specifically correspond to the initiation of goal-
directed behavior and these surges in extracellular DA are temporally associated 
with the inhibition of a majority of NA neurons, and importantly neural inhibition 
associated with DA release is mediated by DA D1 receptors. 
Several researchers have shown that mother-pup interactions result in 
increased DA release into NA (Hansen et al., 1993), and that the amount of DA 
release into NA directly corresponds to the amount of time the mother spends 
interacting with her litter (Champagne et al., 2004). While females spend quite a 
bit of time tending to their newborn infants, mother-pup interaction gently wanes 
as the postpartum period progresses. 
As indicated earlier, several empirical studies have demonstrated that 
interference with the mesolimbic DA system impairs maternal responding. Of the 
24
two DA receptor subtypes (D1 and D2) our laboratory recently determined that 
D1 receptors appear to be mediating the critical effects of DA in NA, and this fits 
with the data already reviewed about DA-D1 effects on NA responsiveness and 
Fos induction. Microinjection of the DA D1 receptor antagonist, SCH 23390, into 
the NA severely disrupted maternal behavior and specifically retrieval behavior, 
with females taking up to 2 hours to collect their pups back at the nest (Numan et 
al., 2005a). Note that these females did not show motor impairments and all 
females promptly approached and sniffed pups. The main deficit was in an 
inability to complete retrieval. Importantly, eticlopride, a D2 antagonist, did not 
disrupt maternal behavior after injection into NA. In addition, SCH 23390 injection 
into a neighboring neural region was not effective. 
Despite that plethora of research on the mesolimbic DA system and the 
regulation of maternal behavior in rats, no one had provided experimental 
evidence that increased DA activity in the NA mediates the transition from pup 
avoidance to pup approach which underlies the onset of maternal behavior at 
parturition. Therefore, the series of experiments included in the first study 
examine the hypothesis that increased DA release and its subsequent action at 
DA D1 receptors in NA mediates increased maternal responsiveness, as well as 
the chemical and anatomical specificity of this idea. The second study examines 
the neural mechanism by which DA action at D1 receptors in the NA promotes 
the onset of maternal behavior. The third study examines the role of estradiol 
stimulation of maternal behavior in an attempt to understand the relationship 
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between DA and E stimulation of maternal behavior. Before I begin describing the 
three studies presented here, I would like to briefly describe one of the methods I 
used in all three studies. 
Probably the most compelling way to provide empirical support for the 
idea that DA release into the NA functions to increase responsiveness would be 
to show that interference with DA activity in the NA blocks behavioral reactivity, 
as well as show that increasing DA activity in the NA promotes responsiveness in 
an unresponsive animal. One challenge in empirically examining the latter is that 
an optimal amount of DA stimulation is probably required to regulate appropriate 
responsiveness toward stimuli, and therefore it is not appropriate to predict that 
increasing DA activity in an animal that is already responding to a particular 
stimulus will improve responding. Instead, supraphysiological amounts of DA 
activity can be equally as detrimental as DAergic depletions (Numan et al., in 
press, Stern and Protomastro, 2000). For example, artificial increases in DA 
activity in NA via large doses of cocaine (50 µg/µl) disrupt maternal behavior 
(Vernotica et al.,1999), and upregulation of DA D1 receptor binding in NA is 
associated with naturally occurring maternal neglect in some strains of mice 
(Gammie et al.,  2008). A better model with which to examine DA regulated 
increases in behavioral responsiveness would be to examine an animal that is 
unresponsive toward a particular stimulus, and examine whether increasing DA 
activity in NA can increase responsiveness toward this particular stimulus. 
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Maternal behavior in rats is an excellent model to address this issue; recall 
that female rats display a dramatic change in maternal responsiveness in 
response to hormonal exposure. To this end, note that females who are exposed 
to the full hormonal events of birth (fully-primed females) not only show an 
immediate onset of maternal behavior, but also show elevated DA release in NA 
in response to pups (Afonso et al., 2009), whereas female rats that are not 
exposed to the full hormonal events of birth do not show appropriate accumbal 
DA responses to pups (Afonso et al., 2008). Recall that partial exposure to the 
hormonal events of pregnancy and parturition via pregnancy termination on day 
15 of pregnancy (15HO) results in partial increased maternal responsiveness, 
such that these females require 2-3 days of pup exposure to show maternal 
behavior. Therefore, in order to examine whether increased DA activity in NA can 
elicit increased maternal responsiveness, we chose to utilize a sub-optimally 
hormone primed female rat, that would not show immediate maternal 
responsiveness upon exposure to pups.  If the increased DA activity in NA of 
fully-hormone primed rats regulates the immediate onset of maternal behavior, 
then it can be hypothesized that sub-optimally hormone-primed rats can be 
induced to show immediate maternal responsiveness after microinjection of DA 
agonists into the NA. 
Importantly, the partially primed 15HO female model was utilized to test 
our hypothesis because it is not likely that DA action on D1 receptors in NA, 
acting alone, would stimulate maternal behavior in naïve virgin females who 
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normally show long sensitization latencies. As reviewed by Numan (2006), 
multiple neural systems are affected by pregnancy hormones to stimulate the 
immediate onset of maternal behavior in parturient females, which includes an 
upregulation of neural systems which promote maternal responsiveness and a 
downregulation of neural systems which inhibit maternal behavior. The 
mesolimbic DA system is conceived of as a component of a facilitatory neural 
system while medial amygdala projections to the caudal anterior hypothalamic 
region are viewed as components of the inhibitory system (see Numan, 2006). 
By partially priming females, it was hoped that the inhibitory system would be 
downregulated sufficiently to allow an experimentally induced upregulation of DA 
activity at D1 receptors in NA to promote full maternal behavior.
II. General Methods
Experimental subjects were nulliparous female rats of the Charles River 
CD strain (Charles River, Wilmington, MA). Each female, 70-100 days of age, 
was mated with a male of the same strain. The day of mating was considered 
day 0 of pregnancy. On the following morning, day 1, females were transferred to 
clear polycarbonate cages (20 X 45 X 20 cm) that contained wood shavings as 
bedding material. On day 14 of pregnancy, females were transferred to clear 
polycarbonate observation cages (50 X 40 X 20 cm), which also contained wood 
shavings for bedding material. The floors of these observation cages were 
divided into four equal compartments by 5-cm high Plexiglas dividers. These 
barriers served to prevent pups from crawling from one quadrant to another. All 
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subjects were maintained under a 12-hr reversed light-dark cycle (lights off at 
0600), and food and water were freely available. Behavioral observations 
occurred during the dark phase and test rooms were illuminated with dim red 
light. 
An additional group of female rats served as donor mothers that provided 
test pups for the experimental females. These Charles River CD females were 
mated and allowed to give birth naturally in polycarbonate cages (20X 45X 20 
cm) containing wood shavings. These females and their litters were housed in a 
different room than the experimental females. 
Cannula implantation was performed on day 1 of pregnancy. This 
stereotaxic surgery was carried out while the rats were under Nembutal 
anesthesia (50 mg/kg, ip) and atropine sulfate pretreatment (0.2 mg/kg, ip). 
Following surgery, females were injected with penicillin (50,000 units/kg, sc) and 
were placed under a warming lamp to recover. Bilateral 22-gauge stainless steel 
guide cannulas (Plastics One, Roanoke, VA) were implanted into the NA. The 
DeGroot (1959) stereotaxic atlas was used and interaural zero served as the 
reference point. Coordinates for NA guide cannula implants were, A 9.5, L ± 1.0, 
V 7.0. The implanted cannulas were cemented to the skull with dental acrylic and 
were occluded with stainless steel stylets that extended 2 mm beyond the end of 
the guide. On day 15 of pregnancy each female was hysterectomized and 
ovariectomized (HO); the operations were preformed by dorsolateral and ventral 
incisions with the animal under nembutal anesthesia. Please note, therefore, that 
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each animal underwent a double survival surgery (cannula implant on day 1 and 
HO on day 15). These procedures, as well as all the other procedures described 
in this thesis, were approved by Boston College’s Institutional Animal Care and 
Use Committee. 
To acclimate females to the intracranial drug administration procedure that 
would begin 48 hrs post-HO, the following procedure was performed at 24 hrs 
post-HO: females were taken to a room outside the maternal behavior testing 
room, and while hand-held, the experimenter removed and replaced the inner 
stylet that kept the guide cannula occluded. 
To perform intracranial injections, the experimenter removed the inner 
stylet from the guide cannula of an awake, hand-held rat and replaced it with a 
28-gauge injector cannula that extended 2 mm beyond the end of the guide. The 
injector cannula was attached to a Hamilton microliter syringe with polyethylene 
tubing, and various doses of a DA agonist were injected into the NA over a 60-s 
interval with the aid of a Sage syringe pump. The injector remained in place for 
an additional 45-s, at which time it was removed and the procedure was repeated 
on the other side of the brain. The injections were performed in a room outside 
the maternal behavior testing room. These injections occurred on the first 3 days 
of behavioral testing (see below)
Pup presentation and behavioral observations commenced between 1000 
and 1100 on each test day and began 48 hours after HO, deemed day 0 of 
testing. On the days that females received intracranial injections (days 0,1, and 2 
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of testing), pup presentation occurred 20 min post-injection. Three stimulus pups 
aged 2-7 days, provided by donor mothers, were placed throughout the cage, 
one in each quadrant which the subject had not used as a sleeping quadrant. 
Care was taken so that younger pups were presented on the earlier days of the 
testing period, whereas older pups were presented later. During the first hr of pup 
exposure, subjects were continuously observed for the first 15 min, spot-checked 
at 30 min, and observed continuously again for the last 15 min of the hour 
observation. Latency to sniff and approach pups was recorded. Females that did 
not sniff the pups by the end of the first 15-min observation were manually 
moved by the experimenter so that they would make snout contact with a pup 
(forced sniff), and such females were assigned a sniff latency of 15 min. During 
the one-hour observation, the location of the female and the pups was noted and 
the occurrence of retrieval responses, nursing behavior (hovering), pup grooming 
and licking, and infanticide were recorded. 
On the first day of behavioral observations, the three stimulus pups were 
placed one at a time in the female’s cage. At the start of the observation period, 
one pup was placed in the quadrant farthest away from the female’s sleeping 
quadrant, at 15 min, a second pup was placed in a separate quadrant, also not 
the female’s sleeping quadrant, and the third pup was placed at the 30 min spot 
check. If the female attacked any of the pups on the first test day, all pups were 
removed and this process was repeated on day 1 of testing. Subjects that 
attacked pups on two consecutive days were excluded from the experiment. 
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[Across the various experiments, approximately 10-15% of females were 
removed from the study because of infanticide. The various groups did not differ 
in the frequency of this behavior]. Females were subsequently given all three 
freshly nourished pups at the start of behavioral observation on the remainder of 
the test days. Approximately 5 hrs post-pup presentation, subjects were spot-
checked, and the locations of the female and the pups were recorded. In order to 
be considered fully maternal in a given test day, subjects had to retrieve all pups 
to a single location, lick and groom pups, and adopt a nursing posture over the 
grouped litter by the end of the 5 hr observation. At the 5-hr observation, if a 
female retrieved and grouped pups, she was observed continuously for 20 min to 
determine whether nursing behavior and pup grooming occurred. Behaviors 
observed during this 20 min were considered to have occurred on that test day. 
The following morning, the location of the subject and the pups was noted, 
the pups were removed, and were replaced with 3 freshly nourished pups (20 
min post injection). This procedure was repeated until subjects showed complete 
maternal behavior during the one hr AM observation for two consecutive 
mornings or until 5 days had elapsed. If complete maternal behavior occurred for 
two consecutive days during drug injections, an additional test was given without 
drug injection in order to show that the maintenance of the behavior was not 
dependent upon drug administration (as it turned out, all females that initiated 
maternal behavior while receiving intracranial injections maintained such 
behavior afterwards). 
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The latency to show maternal behavior was taken as the number of days 
of pup contact preceding the first day on which full maternal behavior was 
displayed. Subjects that did not show maternal behavior during test days 0-5 
were assigned latencies of day 6 for statistical purposes. If a subject showed 
maternal behavior for the first time on day 5 of testing, the subject was tested 
again on day 6 to ensure two consecutive days of complete maternal behavior. 
Based on our observations we were able to compute two main latency measures 
in each female: latency to show full maternal behavior during the first hour of pup 
exposure (hour latency); latency to show full maternal behavior by the end of the 
test day (day latency).
Females were perfused with saline followed by formalin while under deep 
anesthesia. Forty-µm thick brain sections, cut on a freezing microtome, were 
stained with cresyl violet. Microscopic examination mapped the location of the 
cannula injection sites. Females with excessive brain damage or misplaced 
cannula were removed from the study.
For all analyses, a minimum significance level of p = .05 was used. All 
tests were 2-tailed, unless noted otherwise. Ordinal scale data were analyzed 
with nonparametric statistics. The Mann-Whitney U test was used to analyze 
whether median sensitization latencies differed among the independent 
treatment groups. When more than two independent groups were analyzed, the 
Kruskal-Wallis test was used first, and if an overall significant difference was 
detected, then Mann-Whitney U tests were performed for multiple comparisons. 
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For the maternal behavior latency measure, if an overall difference between 
groups was not significant by the Kruskal-Wallis test, we performed the following 
planned comparisons with the Mann-Whitney U test: each drug treatment group 
was compared with the vehicle- injected control. The Fisher exact probability test 
was used for frequency data and the same planned comparisons described 
above were analyzed. Interval scale data were analyzed with t tests, or with 
analysis of variance (ANOVA) followed by the Newman-Keuls test. Interval scale 
data were analyzed with nonparametric statistics rather than ANOVA in cases in 
which there was a lack of homogeneity of variance across multiple groups. 
III.Study 1: Dopamine D1 Receptor Stimulation of the Nucleus Accumbens 
or the Medial Preoptic Area Promotes the Onset of Maternal Behavior in 
Pregnancy Terminated Rats
Experiment 1.1.
 Based on the finding that SCH 23390 injection into NA abolished retrieval 
behavior in postpartum females (Numan et al., 2005a), the central question 
driving the first experiment was whether microinjection of a DA D1 agonist, SKF 
38393, which is considered the compliment to SCH 23390, could produce an 
immediate onset of maternal behavior in 15HO female rats. 
Method
 The purpose of Experiment 1.1 was to determine the effects of bilateral 
injections of various doses of SKF 38393 (a D1 DA receptor agonist obtained 
from Sigma Chemical, St. Louis, MO) into the medial NA on the sensitization 
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latencies of 15HO female rats. This experiment was composed of three 
independent groups receiving either 0µg (vehicle; n = 12), 0.2µg (D1-low; n = 
13), or 0.5µg (D1-high; n = 10) of SKF 38393 into the NA. Each dose of SKF 
38393 was dissolved in 0.5µl of sterile H20 and injected bilaterally on days 0, 1, 
and 2 of behavioral testing. The doses of SKF 38393 were in the range used by 
other investigators (Ikemoto et al., 1997). 
Results
 Experiment 1.1 examined the effects of microinjection of SKF 38393 (a D1 
DA receptor agonist) into the NA on sensitization latencies to show complete 
maternal behavior in 15HO rats (see Table 1.1.1). Although statistical analyses 
did not reveal an overall significant difference among the three groups at either 
the end of the test day or the end of the first hr of observation (Kruskal-Wallis 
One Way ANOVA, H(2) = 4.69, p = .09, H(2) 4.92, p = .08, respectively), planned 
comparisons were made between each dose of SKF 38393 and the vehicle-
injected group. The median latency for females receiving the high dose (0.5 µg) 
of SKF 38393 (n = 10) to show complete maternal behavior by the end of the test 
day was 0.5 days, significantly shorter than the 2-day latency of the vehicle-
treated group (n = 12; Mann-Whitney U test, U = 26.5, p <.023). When the 
median latency to show maternal behavior during the first hr of maternal behavior 
testing was analyzed (rather than by the end of the test day), the 0.5µg group still 
showed maternal behavior significantly sooner (median = 1 day) than the 0 µg 
group (median = 2 days; Mann-Whitney U test, U = 25.5, p = 0.019). The median 
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latency for females receiving the low dose (0.2µg) of SKF 38393 (n = 13) was 1 
day, and was not significantly shorter than the 2-day latency shown by the 
vehicle-treated group (n = 12) during the first hr of observation (Mann-Whitney U 
test, U = 55, p = .19) or by the end of the day (Mann-Whitney U test, U = 53.5, p 
= .16). 
 In addition to analyzing median latencies to onset of complete maternal 
behavior for either the day or the hour, we did the same analysis for each group 
on the latencies to retrieve all pups to the nest. In each group, these latencies 
were identical to those for complete maternal behavior. In other words, given our 
observational methods, fragmented maternal behavior did not occur. Once a 
female retrieved all of her pups to her nest, she also nursed and licked them. 
The cumulative percentages of females in each group showing full 
maternal behavior during the day on each test day are shown in Figure 1.1.1. By 
day 1 of testing, 90% of 15HO females microinjected with the high dose (0.5µg) 
of SKF 38393 into NA showed full maternal behavior compared with only 33% of 
vehicle injected animals. The Fisher exact probability test indicated that this 
difference was significant (p ≤.05). As shown in Table 1.1.1, the mean latency to 
approach and sniff pups (averaged over days 0-2 of testing) did not differ 
between any of the groups (One Way ANOVA, F(2,32) = 0.147, p = .86). 
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Figure 1.1.2 shows reconstructions of the location of the NA injection sites, 
drawn on to the appropriate plates taken from the atlas of Paxinos and Watson 
(1997; on the microtome, the brain sections for both groups were cut in the plane 
of this atlas). Importantly, microscopic analysis of brain sections indicated that for 
each group, all cannula placements were located in the NA, either in the shell 
region or the shell-core border. 
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Table 1.1.1. Outcome Measures in 15HO Rats that Received 0, 0.2, or 0.5µg 
doses of SKF 38393 into the Nucleus Accumbens (NA) 
SKF 38393
Groups N
Mean ± SE latency to 
approach- sniff pups (s)
Median onset to full 
maternal behavior (days)
day hour
Vehicle 12 232.95 ±   82.82 2 (1-4) 2 (1-4)
D1-low 13 271.06 ± 113.30 1 (0-2.5) 1 (0.5-3.5)
D1-high 10 256.40 ± 103.50 0.5*(0-1) 1* (0-1)
 Note: For each female, latency to sniff and approach pups was averaged over 
days 0-2 of testing. Interquartile ranges are shown in parentheses. Abbreviations: 
HO = hysterectomized and ovariectomized. D1 refers to SKF 38393, a DA D1 
agonist. 
* Significantly different from the corresponding vehicle group, Mann-Whitney U 
test. 
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Figure 1.1.1. Cumulative percentage of female rats showing full maternal 
behavior on each test day. Females received bilateral microinjections of either 0 
(vehicle), 0.2 (D1-low), or 0.5 (D1-high) µg of SKF 38393 (ns= 12, 13, 10, 
respectively) into the nucleus accumbens (NA) on days 0, 1, and 2 of testing. 
* Significantly different from vehicle group, Fisher exact probability test.
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Figure 1.1.2. Reconstructions based on the microscopic analysis of cresyl violet 
stained sections of the location of SKF 38393 injection sites (solid squares= 0µg 
dose, open squares= 0.2µg dose, solid circles= 0.5µg dose) into the nucleus 
accumbens (NA), which were drawn onto plates from the Paxinos and Watson 
(1997) atlas. The numbers next to the plates indicate the distance in millimeters 
anterior to the interaural plane. All implant sites were located in either the shell 
region of the nucleus accumbens or on the shell-core border. However, in order 
to facilitate viewing, the depicted locations were spread out slightly to eliminate 
the overlap that actually occurred. 
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Discussion
Experiment 1.1 indicated that microinjection of a DA D1 agonist, SKF 
38393, into the NA promoted maternal responsiveness: the 0.5µg dose resulted 
in a sensitization latency of about 0.5 days, significantly shorter than the 2-day 
latency of the control group. Importantly, 90% of females receiving 0.5 µg of SKF 
38393 were maternal by day 1 of testing compared with only 33% of females in 
the control group. 
In the present experiment, 9 of the 10 females in the 0.5 µg SKF 38393 
treatment group were showing maternal behavior by day 1 of testing. Of these 
nine females, five initiated maternal behavior on day 0 and four showed maternal 
behavior on day 1. Given that SKF 38393 was injected into the NA on days 0, 1, 
and 2 of testing, what accounts for the observed variability in maternal behavior 
initiation? The best explanation is that there is an interaction between each 
female’s baseline maternal responsiveness and the D1 agonist: a certain level of 
maternal responsiveness may be necessary to allow DA-D1 activity in NA to 
push the female over the threshold for full maternal behavior. Some females may 
have had sufficient maternal responsiveness on day 0, while others may have 
required a period of pup stimulation before the DA-D1 agonist could be effective. 
In this context, note that female rats typically give birth on day 22 or 23 of 
pregnancy. Since all female rats were hysterectomized and ovariectomized on 
day 15, it is possible that those females who would have given birth on day 22 
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received a higher level of partial hormonal priming than did the females who 
would have given birth on day 23.
An interesting question is whether DA stimulation of NA caused a higher 
level of maternal behavior than would have been induced by sensitization 
processes alone. To get some information on this point, we examined the time it 
took a female to show complete maternal behavior on the first day during which 
maternal behavior occurred within the one hour morning observation period. 
Most females in the D1-high group were receiving SKF 38393 microinjections 
into NA at this time while the vehicle group did not receive such stimulation. 
When measured from the time of pup presentation on the relevant day, females 
in each of these groups did not differ in the time it took to show complete 
maternal behavior, most doing so in the first 15-30 min of the observation period. 
Therefore, although the vehicle-treated females received more days of pup 
stimulation before showing complete maternal behavior, once the behavior was 
initiated, it occurred as quickly as that displayed by the 0.5 µg group.
Experiment 1.2.
The purpose of Experiment 1.2 was to examine the chemical specificity of 
the finding that DA D1 receptor stimulation of NA promotes the onset of maternal 
behavior in 15HO rats. We hypothesized that agonists at the D2 DA receptor 
would not facilitate the onset of maternal behavior in 15HO females because our 
previous work in postpartum animals showed that D1, but not D2, DA receptor 
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antagonists disrupted maternal behavior when injected into NA (Numan et al., 
2005a). 
Method 
The effects of bilateral injections of quinpirole (a D2 DA receptor agonist 
obtained from Sigma Chemical, St. Louis, MO) on the sensitization latencies of 
15HO female rats were examined. The methods for Experiment 1.2 were 
identical to those of Experiment 1.1 except that subjects received either 0µg 
(vehicle; n = 15), 0.2µg (D2-low; n = 10), or 0.5µg (D2-high; n = 12)/0.5µl per side 
of quinpirole dissolved in sterile H20. Because quinpirole has a molecular weight 
close to SKF 38393 (256 and 292, respectively) the molar doses of these two 
drugs were approximately equivalent across the two experiments. 
Results
 The effects of microinjection of quinpirole (a D2 DA receptor agonist) into 
the NA on sensitization latencies to show complete maternal behavior in 15HO 
are displayed in Table 1.2.1. The Kruskal-Wallis One Way ANOVA indicated there 
was not an overall significant difference between treatment groups by the end of 
the test day or the end of the first hr of observation, (H(2) = 2.65, p = .26, H(2) = 
2.64, p = .27, respectively). Planned comparisons examining each dose of 
quinpirole and the vehicle-treated group also indicated that group differences did 
not exist. The median latency for females receiving either the high dose (0.5 µg) 
of quinpirole (1.5 days; n = 12) or the low dose (0.2 µg) (3 days; n= 10) was not 
significantly different from females which received vehicle injections (median = 2 
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days; n = 15; Mann-Whitney U test, U = 87, p = .84; U = 48.5, p = .13, 
respectively). When the median latency to show maternal behavior during the 
first hr of maternal behavior testing was analyzed (rather than by the end of the 
test day), the differences were also not significant (Mann-Whitney U test, U = 
89.5, p = .94; U = 47.5, p = .12, respectively). There were also no significant 
differences between the groups in mean latency to approach and sniff pups (One 
Way ANOVA, F(2,34) = 0.55, p = 0.58). 
The cumulative percentages of females in each group showing full 
maternal behavior during the day on each test day are shown in Figure 1.2.1. 
The Fisher exact probability test did not detect any significant differences. Figure 
1.2.2 shows reconstructions of the location of the NA injection sites, which were 
all located near the shell-core border and within a range similar to NA injection 
sites for Experiment 1.1. 
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Table 1.2.1. Outcome Measures in 15HO Rats that Received 0, 0.2, or 0.5µg 
doses of Quinpirole into the Nucleus Accumbens (NA) 
Quinpirole
Groups
N Mean ± SE latency to 
approach-sniff pups (s) 
Median onset to full 
maternal behavior (days)
day hour
Vehicle 15 278.00 ± 66.41 2 (0-4) 2 (1-4)
D2-low 10 182.00 ± 67.30 3 (2-5) 3 (2-6)
D2-high 12 212.42 ± 64.93 1.5 (0-5) 1.5 (0-6)
 Note: For each female, latency to sniff and approach pups was averaged over 
days 0-2 of testing. Interquartile ranges are shown in parentheses. Abbreviations: 
HO = hysterectomized and ovariectomized. D2 refers to quinpirole, a DA D2 
agonist. 
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during the first hour of maternal behavior testing (rather than by
the end of the test day) was analyzed, the differences were also not
significant (Mann–Whitney U test, U ! 89.5, p ! .94; U ! 47.5,
p ! .12, respectively). There were also no significant differences
between the groups in mean latency to approach and sniff pups:
one-way ANOVA, F(2, 34) ! 0.55, p ! .58.
The cumulative percentages of females in each group showing
full maternal behavior during the day on each test day are shown
in Figure 3. The Fisher exact probability test did not detect any
significant differences. Figure 4 shows reconstructions of the lo-
cation of the NA injection sites, which were all located near the
shell–core border and within a range similar to NA injection sites
for Experiment 1.
Experiment 3
Experiment 3 examined the effects of microinjection of SKF
38393 into the DS on sensitization latencies to show complete
maternal behavior in 15HO rats (Table 2). The Mann–Whitney U
test indicated there was not a significant difference between the
vehicle-treated females (Mdn ! 3 days; n ! 8) and those treated
with a 0.5-"g dose of SKF 38393 (Mdn ! 6 days; n ! 8) by the
end of the test day (Mann–Whitney U test, U ! 16.5, p ! .08) or
the end of the first hour of observation (U ! 16, p ! .07). Note,
however, that these differences approached significance, implying
that D1 DA receptor stimulation of DS may actually depress
maternal behavior. It is important to note that there was not a
significant difference between the groups in mean latency to
approach and sniff pups, t(14) ! 0.25, p ! .80 (Table 2).
The cumulative percentages of females in each group showing
full maternal behavior during the day on each test day are shown
in Figure 5. Significant differences did not occur. Figure 6 shows
reconstructions of the location of the DS injection sites, drawn
onto the appropriate plates taken from the atlas of Paxinos and
Watson (1997).
Experiment 4
The results of Experiment 4 indicate two important points: First,
the main effect of Experiment 1 was replicated in that the high
dose of SKF 38393 (0.5 "g) was once again effective in reducing
Figure 1. Cumulative percentage of female rats showing full maternal
behavior on each test day. Females received bilateral microinjections of
either 0 (vehicle), 0.2 (D1-low), or 0.5 (D1-high) "g SKF 38393 (ns ! 12,
13, and 10, respectively) into the nucleus accumbens on Days 0, 1, and 2
of testing. *Significantly different from vehicle group, Fisher exact prob-
ability test, p # .05.
Figure 2. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (solid
squares ! 0-"g dose; open squares ! 0.2-"g dose; solid circles ! 0.5-"g
dose) into the nucleus accumbens (NA), which were drawn onto plates
from the Paxinos and Watson (1997) atlas. The numbers next to the plates
indicate the distance in millimeters anterior to the interaural plane. All
implant sites were located in either the shell region of the NA or on the
shell–core border. However, to facilitate viewing, the depicted locations
were spread out slightly to eliminate the overlap that actually occurred.
From The Rat Brain in Stereotaxic Coordinates (3rd ed.), by G. Paxinos
and C. Watson, 1997, San Diego, CA: Academic Press. Copyright 1997 by
Elsevier. Reprinted with permission.
Figure 3. Cumulative percentage of female rats showing full maternal
behavior on each test day. Females received bilateral microinjections of
either 0 (vehicle), 0.2 (D2-low), or 0.5 (D2-high) "g quinpirole (ns ! 15,
10, and 12, respectively) into the nucleus accumbens on Days 0, 1, and 2
of testing. Groups did not significantly differ.
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Figure 1.2.1. Cumulative percentage of female rats showing full maternal 
behavior on each test day. Females received bilateral microinjections of either 0 
(vehicle), 0.2 (D2-low), or 0.5 (D2-high) µg of quinpirole (ns= 15, 10, 12, 
respectively) into the nucleus accumbens (NA) on days 0, 1, and 2 of testing. 
Groups did not significantly differ.
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sensitization latencies when injected bilaterally into NA, and sec-
ond, this high dose of SKF 38393 was able to stimulate maternal
behavior when injected into MPOA (Table 3). The Kruskal–Wallis
one-way ANOVA indicated that there was an overall significant
difference among the four groups during the observation hour,
H(3) ! 9.73, p ! .02, and by the end of the observation day,
H(3) ! 8.30, p " .05. The median latency for females receiving
0.5 #g SKF 38393 into the NA (n ! 8) was 0 days for both the
hour and the day latency measure, and this was significantly
shorter than the 2-day latency of the vehicle-treated group (n ! 8)
during the first hour of observation (Mann–Whitney U test, U !
11.0, p " .05) or the 1.5-day latency for the vehicle group when
measured at the end of the test day (Mann–Whitney U test, U !
12.5, p " .05). The median latency for females receiving 0.5 #g
SKF 38393 into MPOA (n ! 10) was also significantly shorter
than that of the vehicle-treated group during the first hour of
observation (Mann–Whitney U test, U ! 21.5, p " .05) or by the
end of the observation day (Mann–Whitney U test, U ! 24.0, p "
Figure 4. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of quinpirole injection sites (solid
squares ! 0-#g dose; open squares ! 0.2-#g dose; solid circles ! 0.5-#g
dose) into the nucleus accumbens (NA), which were drawn onto plates
from the Paxinos and Watson (1997) atlas. The numbers to the left of the
plates indicate the distance in millimeters anterior to the interaural plane.
All implant sites were located in either the shell region of the NA or on the
shell–core border. However, to facilitate viewing, the depicted locations
were spread out slightly to eliminate the overlap that actually occurred.
From The Rat Brain in Stereotaxic Coordinates (3rd ed.), by G. Paxinos
and C. Watson, 1997, San Diego, CA: Academic Press. Copyright 1997 by
Elsevier. Reprinted with permission.
Figure 5. Cumulative percentage of female rats showing full maternal behavior
on each test day. Females received bilateral microinjections of either 0 (vehicle-
DS) or 0.5 (D1-DS) #g SKF 38393 (ns ! 8 and 8, respectively) into the dorsal
striatum (DS) on Days 0, 1, and 2 of testing. Groups did not differ significantly.
Figure 6. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (open
circles ! 0-#g dose; solid circles ! 0.5-#g dose) into the dorsal striatum
(DS), which were drawn onto plates from the Paxinos and Watson (1997)
atlas. The numbers next to the plates indicate the distance in millimeters
anterior to the interaural plane. From The Rat Brain in Stereotaxic Coor-
dinates (3rd ed.), by G. Paxinos and C. Watson, 1997, San Diego, CA:
Academic Press. Copyright 1997 by Elsevier. Reprinted with permission.
Table 2
Outcome Measures in 15HO Rats That Received 0- or 0.5-#g
Doses of SKF 38393 Into the Dorsal Striatum (DS)
SKF 38393
group N
Mean $ SE
latency to
approach and
sniff pups (s)
Median onset to full
maternal behavior
(days)
Day Hour
Vehicle-DS 8 249.21$ 74.44 2.5 (0–5) 3 (0–5)
D1-DS 8 222.17 $ 77.70 6 (1–6) 6 (3–6)
Note. For each female, latency to sniff and approach pups was averaged
over Days 0–2 of testing. Groups did not differ significantly. Interquartile
ranges are shown in parentheses. D1 refers to SKF 38393, a DA-D1 agonist.
15HO ! hysterectomized and ovariectomized on Day 15 of pregnancy.
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Figure 1.2.2. Reconstructions based on the microscopic analysis of cresyl violet 
stained sections, of the location of quinpirole injection sites (solid squares= 0µg 
dose, open squares= 0.2µg dose, solid circles= 0.5µg dose) into the nucleus 
accumbens (NA), which were drawn onto plates from the Paxin s and Watson 
(1997) atlas. The number  to the left of the plates indicate the distance in 
millimeters anterior to the interaural plane. All implant sites were located in either 
the shell region of the nucleus accumbens or on the shell-core border. However, 
in order to facilitate viewing, the depicted locations were spread out slightly to 
eliminate the overlap that actually occurred.
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Discussion
Experiment 1.2 indicated that within the NA, DAergic facilitation of 
maternal behavior is mediated primarily by D1 receptors, as the D2 receptor 
agonist, quinpirole, did not produce facilitatory effects at the doses tested, which 
were approximate molar equivalents of the SKF 38393 doses. Our results, of 
course, do not rule out the possibility that other doses of quinpirole might have 
been effective. The fact that quinpirole did not produce any facilitatory effects 
when injected into the NA is not unexpected based on our previous research 
which shows that blockade of DA D2 receptors via microinjection of the DA D2 
receptor antagonist, eticlopride, in the NA did not produce any disruptive effects 
on the maternal behavior in postpartum females.  
In examining the results of this experiment, although significant differences 
were not detected, note that the 0.2µg quinpirole-injected females tended to 
show the poorest maternal behavior, with a difference from the 0µg group that 
approached significance. In this regard, note that DA D2 receptors are both 
presynaptic and postsynaptic (Missale et al., 1998). Presynaptic DA receptors 
are located on DA axon terminals in NA and inhibit DA release, which for the 
0.2µg dose, may have caused a slight depression of maternal behavior. To leave 
open the possibility that postsynaptic D2 receptors in NA may contribute to the 
onset of maternal behavior, perhaps the 0.5µg dose of quinpirole acted pre and 
postsynaptically and a positive postsynaptic effect may have subtracted from the 
48
negative presynaptic effect. Therefore, perhaps doses of quinpirole higher than 
0.5µg might have been effective in stimulating the onset of maternal behavior. 
Experiment 1.3.
The purpose of Experiment 1.3 was to determine the anatomical 
specificity of the SKF 38393 effect found in the NA by examining the effects of 
SKF 38393 administration to the dorsal striatum (DS) on maternal behavior. Over 
days 0-2 of behavioral testing, 15HO female rats received bilateral microinjection 
of either SKF 38393 (0.5µg/0.5µl sterile H20/side) or sterile H20 (0.5µl/side) into 
DS [D1-DS (n = 8) and vehicle-DS (n = 8) groups, respectively].
Method
The methods for Experiment 1.3 are identical to those for Experiments 
1.1-1.2, except that bilateral 22-gauge stainless steel guide cannulas were 
implanted into the dorsal striatum (DS). The DeGroot (1959) stereotaxic atlas 
was used and interaural zero served as the reference point. Coordinates for DS 
guide cannula implants were A 8.6, L ± 2.5, V 8.0. The implanted cannulas were 
cemented to the skull with dental acrylic and were occluded with stainless steel 
stylets that extended 2 mm beyond the end of the guide. 
Results
 Experiment 1.3 examined the effects of microinjection of SKF 38393 into 
the DS on sensitization latencies to show complete maternal behavior in 15HO 
rats (Table 1.3.1). The Mann-Whitney U test indicated there was not a significant 
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difference between the vehicle-treated animals and the those treated with a 
0.5µg dose of SKF 38393 by the end of the test day (median = 3 days; n = 8; 
median = 6 days; n = 8; Mann-Whitney U test, U = 16.5, p = .08, respectively), or 
the end of the first hr of observation, (U = 16, p = .07). Note, however, that these 
differences approached significance, implying that D1 DA receptor stimulation of 
DS may actually depress maternal behavior. Importantly, there was not a 
significant difference between the groups in mean latency to approach and sniff 
pups [t(14) = 0.25, p = 0.80 (Table 1.3.1)]. 
The cumulative percentages of females in each group showing full 
maternal behavior during the day on each test day are shown in Figure 1.3.1. 
Significant differences did not occur. Figure 1.3.2 shows reconstructions of the 
location of the DS injection sites, drawn on to the appropriate plates taken from 
the atlas of Paxinos and Watson (1997). Note that the implant sites were located 
in the ventromedial part of the DS, close to the lateral part of the NA.
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Table 1.3.1. Outcome Measures in 15HO Rats that Received 0 or 0.5µg doses of 
SKF 38393 into the Dorsal Striatum (DS)
SKF 38393
Groups N
Mean ± SE latency to 
approach- sniff pups (s)
Median onset to full 
maternal behavior 
(days)
day hour
Vehicle-DS 8 249.21 ± 74.44 2.5 (0-5) 3 (0-5)
D1-DS 8 222.17 ± 77.70 6 (1-6) 6 (3-6)
Note: For each female, latency to sniff and approach pups was averaged over 
days 0-2 of testing. Interquartile ranges are shown in parentheses. Abbreviations: 
HO = hysterectomized and ovariectomized. D1 refers to SKF 38393, a DA D1 
agonist. Groups did not differ significantly.
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sensitization latencies when injected bilaterally into NA, and sec-
ond, this high dose of SKF 38393 was able to stimulate maternal
behavior when injected into MPOA (Table 3). The Kruskal–Wallis
one-way ANOVA indicated that there was an overall significant
difference among the four groups during the observation hour,
H(3) ! 9.73, p ! .02, and by the end of the observation day,
H(3) ! 8.30, p " .05. The median latency for females receiving
0.5 #g SKF 38393 into the NA (n ! 8) was 0 days for both the
hour and the day latency measure, and this was significantly
shorter than the 2-day latency of the vehicle-treated group (n ! 8)
during the first hour of observation (Mann–Whitney U test, U !
11.0, p " .05) or the 1.5-day latency for the vehicle group when
measured at the end of the test day (Mann–Whitney U test, U !
12.5, p " .05). The median latency for females receiving 0.5 #g
SKF 38393 into MPOA (n ! 10) was also significantly shorter
than that of the vehicle-treated group during the first hour of
observation (Mann–Whitney U test, U ! 21.5, p " .05) or by the
end of the observation day (Mann–Whitney U test, U ! 24.0, p "
Figure 4. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of quinpirole injection sites (solid
squares ! 0-#g dose; open squares ! 0.2-#g dose; solid circles ! 0.5-#g
dose) into the nucleus accumbens (NA), which were drawn onto plates
from the Paxinos and Watson (1997) atlas. The numbers to the left of the
plates indicate the distance in millimeters anterior to the interaural plane.
All implant sites were located in either the shell region of the NA or on the
shell–core border. However, to facilitate viewing, the depicted locations
were spread out slightly to eliminate the overlap that actually occurred.
From The Rat Brain in Stereotaxic Coordinates (3rd ed.), by G. Paxinos
and C. Watson, 1997, San Diego, CA: Academic Press. Copyright 1997 by
Elsevier. Reprinted with permission.
Figure 5. Cumulative percentage of female rats showing full maternal behavior
on each test day. Females received bilateral microinjections of either 0 (vehicle-
DS) or 0.5 (D1-DS) #g SKF 38393 (ns ! 8 and 8, respectively) into the dorsal
striatum (DS) on Days 0, 1, and 2 of testing. Groups did not differ significantly.
Figure 6. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (open
circles ! 0-#g dose; solid circles ! 0.5-#g dose) into the dorsal striatum
(DS), which were drawn onto plates from the Paxinos and Watson (1997)
atlas. The numbers next to the plates indicate the distance in millimeters
anterior to the interaural plane. From The Rat Brain in Stereotaxic Coor-
dinates (3rd ed.), by G. Paxinos and C. Watson, 1997, San Diego, CA:
Academic Press. Copyright 1997 by Elsevier. Reprinted with permission.
Table 2
Outcome Measures in 15HO Rats That Received 0- or 0.5-#g
Doses of SKF 38393 Into the Dorsal Striatum (DS)
SKF 38393
group N
Mean $ SE
latency to
approach and
sniff pups (s)
Median onset to full
maternal behavior
(days)
Day Hour
Vehicle-DS 8 249.21$ 74.44 2.5 (0–5) 3 (0–5)
D1-DS 8 222.17 $ 77.70 6 (1–6) 6 (3–6)
Note. For each female, latency to sniff and approach pups was averaged
over Days 0–2 of testing. Groups did not differ significantly. Interquartile
ranges are shown in parentheses. D1 refers to SKF 38393, a DA-D1 agonist.
15HO ! hysterectomized and ovariectomized on Day 15 of pregnancy.
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Figure 1.3.1. Cumulative percentage of female rats showing full maternal 
behavior on each test day. Females received bilateral microinjections of either 0 
(vehicle-DS) or 0.5 (D1-DS) µg of SKF 38393 (ns= 8, 8, respectively) into the 
dorsal striatum (DS) on days 0, 1, and 2 of testing. Groups did not differ 
significantly.
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sensitization latencies when injected bilaterally into NA, and sec-
ond, this high dose of SKF 38393 was able to stimulate maternal
behavior when injected into MPOA (Table 3). The Kruskal–Wallis
one-way ANOVA indicated that there was an overall significant
difference among the four groups during the observation hour,
H(3) ! 9.73, p ! .02, and by the end of the observation day,
H(3) ! 8.30, p " .05. The median latency for females receiving
0.5 #g SKF 38393 into the NA (n ! 8) was 0 days for both the
hour and the day latency measure, and this was significantly
shorter than the 2-day latency of the vehicle-treated group (n ! 8)
during the first hour of observation (Mann–Whitney U test, U !
11.0, p " .05) or the 1.5-day latency for the vehicle group when
measured at the end of the test day (Mann–Whitney U test, U !
12.5, p " .05). The median latency for females receiving 0.5 #g
SKF 38393 into MPOA (n ! 10) was also significantly shorter
than that of the vehicle-treated group during the first hour of
observation (Mann–Whitney U test, U ! 21.5, p " .05) or by the
end of the observation day (Mann–Whitney U test, U ! 24.0, p "
Figure 4. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of quinpirole injection sites (solid
squares ! 0-#g dose; open squares ! 0.2-#g dose; solid circles ! 0.5-#g
dose) into the nucleus accumbens (NA), which were drawn onto plates
from the Paxinos and Watson (1997) atlas. The numbers to the left of the
plates indicate the distance in millimeters anterior to the interaural plane.
All implant sites were located in either the shell region of the NA or on the
shell–core border. However, to facilitate viewing, the depicted locations
were spread out slightly to eliminate the overlap that actually occurred.
From The Rat Brain in Stereotaxic Coordinates (3rd ed.), by G. Paxinos
and C. Watson, 1997, San Diego, CA: Academic Press. Copyright 1997 by
Elsevier. Reprinted with permission.
Figure 5. Cumulative percentage of female rats showing full maternal behavior
on each test day. Females received bilateral microinjections of either 0 (vehicle-
DS) or 0.5 (D1-DS) #g SKF 38393 (ns ! 8 and 8, respectively) into the dorsal
striatum (DS) on Days 0, 1, and 2 of testing. Groups did not differ significantly.
Figure 6. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (open
circles ! 0-#g dose; solid circles ! 0.5-#g dose) into the dorsal striatum
(DS), which were drawn onto plates from the Paxinos and Watson (1997)
atlas. The numbers next to the plates indicate the distance in millimeters
anterior to the interaural plane. From The Rat Brain in Stereotaxic Coor-
dinates (3rd ed.), by G. Paxinos and C. Watson, 1997, San Diego, CA:
Academic Press. Copyright 1997 by Elsevier. Reprinted with permission.
Table 2
Outcome Measures in 15HO Rats That Received 0- or 0.5-#g
Doses of SKF 38393 Into the Dorsal Striatum (DS)
SKF 38393
group N
Mean $ SE
latency to
approach and
sniff pups (s)
Median onset to full
maternal behavior
(days)
Day Hour
Vehicle-DS 8 249.21$ 74.44 2.5 (0–5) 3 (0–5)
D1-DS 8 222.17 $ 77.70 6 (1–6) 6 (3–6)
Note. For each female, latency to sniff and approach pups was averaged
over Days 0–2 of testing. Groups did not differ significantly. Interquartile
ranges are shown in parentheses. D1 refers to SKF 38393, a DA-D1 agonist.
15HO ! hysterectomized and ovariectomized on Day 15 of pregnancy.
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Figure 1.3.2. Reconstructi ns, based on the microscop c analysis of cresyl violet 
stained section , of the lo ation of SKF 38393 inj ction sites (open circles= 0µg 
dose, solid circles= 0.5µg dose) into  dorsal striatum (DS), which were drawn 
onto plates from the Paxinos nd Watson (1997) atlas. The numbers next to the 
plates indicate the distance in illimeters anterior to the nteraural plane. 
53
Discussion
 The results indicate that the the facilitatory effect of D1 activation in the NA 
on maternal behavior was also shown to be relatively site specific, as the dose of 
SKF 38393 which was effective in stimulating maternal behavior when injected 
into the NA failed to facilitate maternal behavior when injected into the DS. In 
fact, data obtained from Experiment 3 show that SKF 38393 injections into the 
DS tended to inhibit maternal responding compared with controls, although this 
trend was not significant.
Experiment 1.4
Although our hypothesis is that stimulation of DA D1 receptors in NA 
would promote the onset of maternal behavior in 15HO females, we also 
examined whether increased DA D1 receptor stimulation in MPOA would 
promote maternal behavior. As reviewed in the Introduction, recall that the 
MPOA is critical for the onset and maintenance of maternal behavior. Several 
pieces of evidence indicate that DA action at the level of the MPOA might also 
participate in the regulation of the onset and maintenance of maternal behavior in 
rats; (a) MPOA receives DA input from diencephalic sources (Simerly et al., 
1986), (b) expresses both D1 and D2 receptors (Bakowska and Morrell, 1995); 
(c) DA activity in the MPOA fluctuates throughout pregnancy and lactation 
(Lonstein et al., 2003; Olazabel et al., 2004); (d) high doses (5 µg) of D1 
antagonists injected directly into the MPOA have been found to disrupt maternal 
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behavior in postpartum rats, and the nature of the disruption is similar to that 
observed after D1 antagonist injection into NA (Miller and Lonstein, 2005).
Using the 15HO model, we examined whether the 0.5 µg dose of SKF 
38393, which effectively stimulated maternal behavior when injected into the 
medial NA, could produce similar effects when injected into MPOA. We chose to 
examine four independent groups of females who received either 0 or 0.5µg of 
SKF 38393 into either NA or MPOA, which allowed us to directly compare the 
effects of SKF 38393 microinjection into these two important regions. 
Method
The methods used were similar to those described for Experiment 1.1, 
except for the following details. Four groups were formed based on the injections 
received on days 0-2 of testing. D1-MPOA (n = 10): 0.5µg SKF 38393/0.5µl 
sterile H20/side; vehicle-MPOA (n = 10): 0.5 µl sterile H20/side; D1-NA (n = 8): 
0.5µg SKF 38393/ 0.5µl sterile H20/side; vehicle-NA (n = 8): 0.5µl sterile H20/
side. Bilateral 22-gauge stainless steel guide cannulas implanted into either the 
NA or the MPOA. Coordinates (DeGroot, 1959) for MPOA guide cannula implants  
were, A 7.5, L ± 0.75, V 5.8. The implanted cannulas were cemented to the skull 
with dental acrylic and were occluded with stainless steel stylets that extended 2 
mm beyond the end of the guide. 
In this experiment we also determined whether SKF 38393 administration 
had an effect on general locomotor activity. On days 0-2 of testing, over the 3 
minutes prior to pup presentation (17-20 min post-injection), the absolute number 
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of line crosses (movement of all four feet from one quadrant to another as 
defined by the Plexiglas dividers) performed by each female was recorded. 
Results
 The results of Experiment 1.4 indicate two important points: first, the main 
effect of Experiment 1.1 was replicated in that the high dose of SKF 38393 
(0.5µg) was once again effective in reducing sensitization latencies when injected 
bilaterally into the medial NA, and secondly, this high dose of SKF 38393 was 
also able to stimulate maternal behavior when injected into MPOA (Table 1.4.1). 
The Kruskal-Wallis One Way ANOVA indicated that there was an overall 
significant difference among the four groups during the observation hr, [H(3) = 
9.73, p = .02], and by the end of the observation day [H(3) = 8.30, p < 0.05]. The 
median latency for females receiving 0.5µg of SKF 38393 into the NA (n = 8) was 
0 days for both the hr and the day latency measure, and this was significantly 
shorter than the 2-day latency of the corresponding vehicle-NA group (n = 8) 
during the first hr of observation (Mann-Whitney U test, U = 11, p < 0.05) or the 
1.5 day latency for the vehicle group when measured at the end of the test day 
(Mann-Whitney U test, U = 12.5, p < 0.05). The median latency for females 
receiving 0.5µg of SKF 38393 into MPOA (n = 10) was also significantly shorter 
than the vehicle-treated group during the first hr of observation (Mann-Whitney U 
test, U = 21.5, p < 0.05) or by the end of the observation day (Mann-Whitney U 
test, U = 24, p < 0.05). There were no significant differences between the median 
latencies for females receiving SKF 38393 injections into NA versus MPOA, nor 
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were there significant differences between median latencies of vehicle treated 
animals who received injections into NA or MPOA. A one way ANOVA indicated 
there were not significant differences between treatment groups (see Table 1.4.1) 
in the latency to approach and sniff pups, F(3,32) = 1.80, p = .17, or in home 
cage activity in the 3 min prior to pup presentation [(Kruskal-Wallis One Way 
ANOVA) H(3) = 3.37, p = .29]. Sniff latencies and home cage line crosses were 
averaged across days 0-2 of testing. 
 In addition to analyzing median latencies to onset of complete maternal 
behavior for either the day or the hour, we did the same analysis for each group 
on the latencies to retrieve all pups to the nest. In each group, these latencies 
were identical to those for complete maternal behavior. Therefore, similar to the 
results obtained for Experiment 1.1, fragmented maternal behavior did not occur 
in Experiment 1.4. Once a female retrieved all of her pups to her nest, she also 
nursed and licked them.
 The cumulative percentages of females showing complete maternal 
behavior on each test day are shown in Figure 1.4.1. By the end of day 0 of 
testing, 80% of the females receiving SKF 38393 into MPOA showed complete 
maternal behavior compared with only 20% of vehicle-treated animals. Fisher 
exact probability test indicated that this difference was significant (p < 0.05). 
Although 62.5% of females injected with SKF 38393 into NA showed complete 
maternal behavior by the end of day 0 of testing, compared with only 14% of 
vehicle-injected animals, this difference only approached significance (p = .07); if 
57
a larger number of subjects had been run it is likely that a significant effect would 
have been observed. Figure 1.4.2 shows reconstructions of the location of 
MPOA injection sites and Figure 1.4.3 shows reconstructions of the location of 
NA injection sites. 
 In order to examine whether DA stimulation of NA or MPOA caused a 
higher level of maternal behavior than would have been induced by sensitization 
processes alone, we examined the time it took a female to show complete 
maternal behavior on the first day during which maternal behavior occurred 
within the one-hour morning observation period. Most females in the D1-NA and 
D1-MPOA groups were receiving SKF 38393 microinjections at this time while 
the vehicle groups were not receiving such stimulation. Females in each of these 
four groups did not differ in the time it took them to show complete maternal 
behavior, most doing so in the first 15-30 min of the observation period. These 
results conform with those of Experiment 1.1.
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Table 1.4.1. Outcome Measures in 15HO Rats that Received 0 or 0.5µg doses of 
SKF 38393 into the Nucleus Accumbens (NA) or Medial Preoptic Area (MPOA)
Groups N
Mean ± SE latency to 
approach- sniff pups (s)
Median onset to full 
maternal behavior (days)
day hour
Vehicle-NA   8 265.96 ± 82.61 1.5 (1-6) 2 (1-6)
D1-NA   8 153.21 ± 51.64 0* (0-1) 0* (0-1)
Vehicle-MPOA 10   87.37 ± 38.38 1 (1-4) 1.5 (1-4)
D1-MPOA 10 179.29 ± 45.27 0* (0-0) 0* (0-1)
Note: For each female, latency to sniff and approach pups and number of line 
crosses  were averaged over days 0-2 of testing. Interquartile ranges are shown 
in parentheses. Abbreviations: HO = hysterectomized and ovariectomized. D1 
refers to SKF 38393, a DA D1 agonist. 
*Significantly different from the corresponding vehicle group, Mann-Whitney U 
test.
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Figure 1.4.1. Cumulative percentage of female rats showing full maternal 
behavior on each test day. Females received bilateral microinjections of either 0 
(vehicle-NA) or 0.5 (D1-NA) µg of SKF 38393 (ns= 8, 8 respectively) into the 
nucleus accumbens (NA) on days 0, 1, and 2 of testing, or 0 (vehicle-MPOA) or 
0.5 (D1-MPOA) µg of SKF 38393 (ns= 10, 10 respectively) into the medial 
preoptic area (MPOA). * Significantly different from vehicle- MPOA group, Fisher 
exact probability test.
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can substitute for estradiol in the stimulation of maternal behavior
in 15HO females.
Experiment 1 indicated that microinjection of a D1 DA agonist,
SKF 38393, into the NA promoted maternal responsiveness: The
0.5-!g dose resulted in a sensitization latency of about 0.5 days,
significantly shorter than the 2-day latency of the control group. Of
note, 90% of females receiving 0.5 !g SKF 38393 were maternal
by Day 1 of testing compared with only 33% of females in the
control group.
Experiment 2 indicated that within the NA, dopaminergic facil-
itation of maternal behavior is mediated primarily by D1 receptors,
as the D2 receptor agonist quinpirole did not produce facilitatory
effects at the doses tested, which were approximate molar equiv-
alents of the SKF 38393 doses. Our results, of course, do not rule
out the possibility that other doses of quinpirole might have been
effective.
The facilitatory effect of D1 activation in the NA on maternal
behavior was also shown to be relatively site specific, as the dose
of SKF 38393 that was effective in stimulating maternal behavior
when injected into the NA failed to facilitate maternal behavior
when injected into the DS. In fact, data obtained from Experiment
3 show that SKF 38393 injections into the DS tended to inhibit
maternal responding compared with controls, although this trend
was not significant.
Experiment 4 demonstrated that increased D1 receptor activa-
tion in either the NA or the MPOA was capable of facilitating
maternal behavior. Not only do these findings validate the results
of Experiment 1, but they also suggest a role for dopaminergic
mechanisms within the MPOA in the regulation of the onset of
maternal behavior. Of note, there were no differences between the
effects of SKF 38393 microinjection into the NA and MPOA,
indicating that increased D1 DA activation in each region produced
equivalent effects on maternal responding.
In Experiment 1, 9 of the 10 females in the 0.5-!g SKF 38393
treatment group were showing maternal behavior by Day 1 of
testing. Of these 9 females, 5 initiated maternal behavior on Day 0
and 4 showed maternal behavior on Day 1. Given that SKF 38393
was injected into the NA on Days 0, 1, and 2 of testing, what
accounts for the observed variability in maternal behavior initia-
tion? The best explanation is that there is an interaction between
each female’s baseline maternal responsiveness and the D1 ago-
nist: A certain level of maternal responsiveness may be necessary
to allow D1 DA activity in NA to push the female over the
threshold for full maternal behavior. Some females may have had
sufficient maternal responsiveness on Day 0, whereas others may
have required a period of pup stimulation before the D1 DA
agonist could be effective. In this context, note that female rats
typically give birth on Day 22 or 23 of pregnancy. Because all
female rats were hysterectomized and ovariectomized on Day 15,
it is possible that those females that would have given birth on Day
Figure 8. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (solid
squares" 0-!g dose; solid circles" 0.5-!g dose) into the medial preoptic
area (MPOA), which were drawn onto plates from the Paxinos and Watson
(1997) atlas. The numbers to the left of the plates indicate the distance in
millimeters anterior to the interaural plane. All implants were located
within the MPOA or the ventral bed nucleus of the stria terminalis.
However, to facilitate viewing, the depicted locations were spread out
slightly to eliminate the overlap that actually occurred. From The Rat Brain
in Stereotaxic Coordinates (3rd ed.), by G. Paxinos and C. Watson, 1997,
San Diego, CA: Academic Press. Copyright 1997 by Elsevier. Reprinted
with permission.
Figure 9. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (open
circles " 0-!g dose; solid circles " 0.5-!g dose) into the nucleus accum-
bens, which were drawn onto plates from the Paxinos and Watson (1997)
atlas. The numbers next to the plates indicate the distance in millimeters
anterior to the interaural plane. From The Rat Brain in Stereotaxic Coor-
dinates (3rd ed.), by G. Paxinos and C. Watson, 1997, San Diego, CA:
Academic Press. Copyright 1997 by Elsevier. Reprinted with permission.
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Figure 1.4.2. Reconstructions, based on the microscopic analysis of cresyl violet 
stained sections, of the location of SKF 38393 injection sites (solid squares= 0µg 
dose, solid circles= 0.5µg dose) into the medial preoptic area (MPOA), which 
were drawn onto plates from the Paxinos and Watson (1997) atlas. The numbers 
to the left of the plates indicate the distance in millimeters anterior to th  
interaural plane. All implants were located within the medial preoptic area or the 
ventral bed nucleus of the stria terminalis. However, in order to facilitate viewing, 
the depicted locations were spread out slightly to eliminate the overlap that 
actually occurred.
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can substitute for estradiol in the stimulation of maternal behavior
in 15HO females.
Experiment 1 indicated that microinjection of a D1 DA agonist,
SKF 38393, into the NA promoted maternal responsiveness: The
0.5-!g dose resulted in a sensitization latency of about 0.5 days,
significantly shorter than the 2-day latency of the control group. Of
note, 90% of females receiving 0.5 !g SKF 38393 were maternal
by Day 1 of testing compared with only 33% of females in the
control group.
Experiment 2 indicated that within the NA, dopaminergic facil-
itation of maternal behavior is mediated primarily by D1 receptors,
as the D2 receptor agonist quinpirole did not produce facilitatory
effects at the doses tested, which were approximate molar equiv-
alents of the SKF 38393 doses. Our results, of course, do not rule
out the possibility that other doses of quinpirole might have been
effective.
The facilitatory effect of D1 activation in the NA on maternal
behavior was also shown to be relatively site specific, as the dose
of SKF 38393 that was effective in stimulating maternal behavior
when injected into the NA failed to facilitate maternal behavior
when injected into the DS. In fact, data obtained from Experiment
3 show that SKF 38393 injections into the DS tended to inhibit
maternal responding compared with controls, although this trend
was not significant.
Experiment 4 demonstrated that increased D1 receptor activa-
tion in either the NA or the MPOA was capable of facilitating
maternal behavior. Not only do these findings validate the results
of Experiment 1, but they also suggest a role for dopaminergic
mechanisms within the MPOA in the regulation of the onset of
maternal behavior. Of note, there were no differences between the
effects of SKF 38393 microinjection into the NA and MPOA,
indicating that increased D1 DA activation in each region produced
equivalent effects on maternal responding.
In Experiment 1, 9 of the 10 females in the 0.5-!g SKF 38393
treatment group were showing maternal behavior by Day 1 of
testing. Of these 9 females, 5 initiated maternal behavior on Day 0
and 4 showed maternal behavior on Day 1. Given that SKF 38393
was injected into the NA on Days 0, 1, and 2 of testing, what
accounts for the observed variability in maternal behavior initia-
tion? The best explanation is that there is an interaction between
each female’s baseline maternal responsiveness and the D1 ago-
nist: A certain level of maternal responsiveness may be necessary
to allow D1 DA activity in NA to push the female over the
threshold for full maternal behavior. Some females may have had
sufficient maternal responsiveness on Day 0, whereas others may
have required a period of pup stimulation before the D1 DA
agonist could be effective. In this context, note that female rats
typically give birth on Day 22 or 23 of pregnancy. Because all
female rats were hysterectomized and ovariectomized on Day 15,
it is possible that those females that would have given birth on Day
Figure 8. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (solid
squares" 0-!g dose; solid circles" 0.5-!g dose) into the medial preoptic
area (MPOA), which were drawn onto plates from the Paxinos and Watson
(1997) atlas. The numbers to the left of the plates indicate the distance in
millimeters anterior to the interaural plane. All implants were located
within the MPOA or the ventral bed nucleus of the stria terminalis.
However, to facilitate viewing, the depicted locations were spread out
slightly to eliminate the overlap that actually occurred. From The Rat Brain
in Stereotaxic Coordinates (3rd ed.), by G. Paxinos and C. Watson, 1997,
San Diego, CA: Academic Press. Copyright 1997 by Elsevier. Reprinted
with permission.
Figure 9. Reconstructions, based on the microscopic analysis of cresyl
violet stained sections, of the location of SKF 38393 injection sites (open
circles " 0-!g dose; solid circles " 0.5-!g dose) into the nucleus accum-
bens, which were drawn onto plates from the Paxinos and Watson (1997)
atlas. The numbers next to the plates indicate the distance in millimeters
anterior to the interaural plane. From The Rat Brain in Stereotaxic Coor-
dinates (3rd ed.), by G. Paxinos and C. Watson, 1997, San Diego, CA:
Academic Press. Copyright 1997 by Elsevier. Reprinted with permission.
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Figure 1.4.3. Reconstructions, based on the microscopic analysis of cresyl violet 
stained s ctions, of th  loca ion of SKF 38393 injection sites (open circles= 0µg 
dose, solid circles= 0.5µg dose) into the nucleus accumbens (NA), which were 
drawn onto plates from the Paxinos and Watson (1997) atlas. The numbers next 
to the plates indicate the distance in millimeters anterior to the interaural plane.
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Discussion
Experiment 1.4 demonstrated that increased D1 receptor activation in 
either the NA or the MPOA was capable of facilitating maternal behavior. Not only 
do these findings validate the results of Experiment 1.1, but they also suggest a 
role for DAergic mechanisms within the MPOA in the regulation of the onset of 
maternal behavior. Importantly, there were no differences between the effects of 
SKF 38393 microinjection into the NA and MPOA, indicating that increased DA-
D1 activation in each region produced equivalent effects on maternal responding. 
One possible interpretation of the finding that SKF 38393 significantly 
reduced sensitization latencies is that administration of the DA agonist altered 
motor activity and therefore females treated with SKF 38393 had an increased 
opportunity to come into contact with pups. This interpretation is highly unlikely, 
however, because the latency to approach and sniff pups was not significantly 
different between treatment groups. Additionally, Experiment 1.4 showed that in 
the three min prior to pup presentation, groups did not differ in home cage 
activity. Finally, casual observation indicated that differences in general motor 
activity did not occur.
Concerning the location of the implant sites, histological analysis indicated 
that MPOA implant sites were similar between vehicle and SKF 38393 injected 
animals. NA implant sites were all located within the shell region of the NA or the 
shell-core border in Experiments 1.1, 1.2, and 1.4. This finding fits with previous 
work that suggests the importance of the shell region for maternal behavior (Keer 
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and Stern, 1999; Li and Fleming, 2003; Numan et al, 2005a; Stack et al., 2002). 
Analysis of the rostro-caudal location of the NA implant sites in the SKF 38393 
treated females in Experiments 1.1 and 1.4 indicated that there was no 
relationship between anterior-posterior injection location and onset latency.
Because the present experiment found that SKF 38393 microinjection into 
either the NA or MPOA was capable of facilitating maternal behavior, probably 
the most central question that future research will have to resolve is whether SKF 
38393 is actually capable of facilitating maternal behavior by acting at either of 
these sites. In other words, the possibility remains open that the D1 agonist had 
its primary effect at only one of these two sites and the facilitatory effect observed 
at the other site was due to spread of the drug to the primary site (the NA and the 
MPOA implant sites were only separated by about 2 millimeters). 
With respect to the possibility that the primary site of action of SKF 38393 
is at the level of the NA, the following should be noted. For postpartum females, 
Numan et al. (2005a) were able to depress maternal behavior with microinjection 
of SCH 23390 (a D1 antagonist) into the NA at a dosage level (1-2 micrograms) 
which was ineffective when injected into the MPOA. The depressive effect of 
SCH 23390 into NA therefore, cannot be explained by spread of the antagonist to 
the MPOA. Supporting the results of Numan et al. (2005a), Miller and Lonstein 
(2005) also found that bilateral injections of a 2 µg dose of SCH 23390 into the 
MPOA did not affect maternal behavior. However, these same authors found that 
bilateral MPOA injections of 5 µg of the D1 antagonist did disrupt maternal 
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behavior. These results suggest the possibility that the disruptive effects reported 
by Miller and Lonstein (2005) were due to spread of the 5 µg dose of SCH 23390 
from the MPOA to the NA. We cannot rule out the possibility however, that in 
postpartum females small doses of SCH 23390 in NA effectively depress 
maternal behavior, while direct action of this drug in the MPOA requires higher 
doses. 
In spite of the difficulty interpreting the effects on maternal behavior of D1 
antagonism at the level of the MPOA, other research supports the possibility that 
in addition to an action on the NA, DA action on the MPOA is also important for 
maternal behavior. This research draws on parallels between the neural 
regulation of maternal behavior and male sexual behavior in rats. In particular, 
MPOA lesions disrupt both behaviors, and E action on the MPOA not only 
facilitates maternal behavior, but also promotes male sexual behavior (Numan, 
1974,1985). Significantly, DA activity in the MPOA is integral to the regulation of 
male sexual behavior (Hull and Dominguez, 2006). Blockade of DA receptors in 
the MPOA has been found to impair copulation, microinjection of DA agonists into 
the MPOA facilitates copulation, and DA is released into the MPOA both in the 
presence of a receptive female and during mating behavior (Dominguez and Hull, 
2005). Furthermore, DA activity in the MPOA is regulated by male sex hormones 
and this hormonal regulation of DA release has been linked to a mechanism 
involving the gaseous neuromodulator nitric oxide (NO) (Hull and Dominguez, 
2006). Disruption of NO synthesis by microinjection of L-NAME (NO synthase 
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inhibitor) not only impairs copulation (Lagoda et al., 2004) but also disrupts DA 
release in response to a receptive female (Dominguez et al., 2005). 
Importantly, there is also evidence to indicate that NO is important for the 
expression of maternal behavior in rats: Popeski and Woodside (2004) showed 
that intracerebroventricular injection of L-NAME disrupts maternal behavior. The 
recent finding that microinjection of L-NAME directly into the MPOA also disrupts 
maternal behavior (Service and Woodside, 2007), and that this effect can be 
reversed with simultaneous injections of SKF 38393 (Service and Woodside, 
2006), suggests that NO may be similarly involved in the regulation of DA release 
in the MPOA during maternal behavior, and this may provide a mechanism 
through which the MPOA regulates the onset of maternal responsiveness. 
 Interestingly, there is also evidence to suggest that E action on NA can 
facilitate DA transmission in NA (Becker, 1999) and because the NA also 
contains nitric oxide synthase (NOS) neurons and NO is involved in regulating 
NA function (West, Galloway, & Grace, 2002), an important question concerns 
the similarity in underlying mechanisms between DA action on these two 
structures.
 With respect to this question, it would be to interesting to explore the 
effects of doses of SKF 38393 into MPOA that are lower than 0.5µg on the onset 
of maternal behavior in 15HO rats. If 0.2µg were to be effective it could be 
argued strongly for an MPOA site of action, since this dose was not effective in 
NA.
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Finally, note that the Numan et al (2005a) and Miller and Lonstein (2005) 
studies deal with the maintenance of maternal behavior during the postpartum 
period, after its initiation. It is entirely possible that the brain mechanisms 
regulating the onset of maternal behavior differ from those regulating the 
maintenance of maternal behavior, in the same manner as hormones being 
necessary for the onset of maternal behavior, are not required for its 
maintenance. Therefore, perhaps DA-D1 input to NA is necessary for both the 
onset and the maintenance of maternal behavior, while DA D1 input to the 
MPOA has its major influence only on the onset of maternal behavior.
General Discussion 
Previous research has shown that depression of DA action on the NA 
disrupts maternal behavior in postpartum female rats (Keer and Stern, 1999), 
and has emphasized the involvement of D1 receptors (Numan et al., 2005a). As 
an important compliment to these findings, study 1 provides substantial evidence 
that increased DA activity at D1 receptors in the NA promotes maternal behavior. 
In addition, our findings indicate that the MPOA, but not the DS, is another site 
where D1 receptor activation promotes maternal behavior. These results suggest 
that increased DA activity at D1 receptors in the NA or MPOA can substitute for 
estradiol in the stimulation of maternal behavior in 15HO females.
In the present study we were primarily concerned with the mechanism 
regulating the onset of complete maternal behavior (retrieving, nursing, and 
licking pups), and we did not take detailed observations on the intensity of 
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maternal behavior after it was initiated. An interesting question for future 
investigation might be to examine whether the intensity of maternal behavior 
(amount of nursing and licking pups) is superior in females that received SKF 
38393 stimulation of either NA or MPOA when compared to the maternal 
behavior of control females. Based on the fact that once maternal behavior is 
initiated it is controlled by endogenous DA activity, our inclination, backed up by 
some observations during the current study, is that there would not be a 
difference in the nature of maternal behavior between SKF 38393 and vehicle 
injected females. In particular, on the first day that females showed complete 
maternal behavior within the one-hour morning observation, females typically 
showed the behavior within 15-30 min of pup presentation irrespective of whether 
they were receiving SKF 38393 microinjections into the brain. That is, SKF 
38393- and vehicle-treated females did not differ in the speed to show the 
complete maternal behavior pattern once the behavior had been initiated. In 
further support, it has been found that in home cage tests, the maternal 
behaviors shown by sensitized virgins are virtually indistinguishable from those 
shown by postpartum lactating females (Fleming and Rosenblatt, 1974; Reisbick 
et al., 1975). Additionally, note that endogenous DA levels are higher in the 
MPOA of sensitized virgins compared with controls (Olazabel et al., 2004). 
However, we cannot rule out the possibility that SKF 38393 injection caused 
supernormal levels of D1 stimulation which might have caused higher levels of 
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various maternal behaviors in terms of the durations of the behaviors (see 
Champagne et al., 2004).
While it is clear that DA activity in NA is critical for both the onset and 
maintenance of maternal behavior, the role of DA in MPOA is less understood. 
Despite the discrepancy in data with respect to the disruptive effect of SCH 
23390 injections into MPOA, our working hypothesis, based on the results of the 
present study, is that it is likely that D1-DA receptor activation in both MPOA and 
NA is important for the onset of maternal behavior. In this context, recall that the 
MPOA and mesolimbic DA system are linked in the control of maternal behavior.  
Our lab has developed a model in which the MPOA plays a role in the regulation 
of maternal responsiveness through its activation of the mesolimbic DA system 
via projections to the VTA (see Numan, 2006; Numan et al., 2005b): as a result of 
hormonal stimulation, the MPOA is primed to respond to certain pup stimuli. The 
MPOA, in turn activates the VTA-DA projections to NA which ultimately, through a 
process of disinhibition, allow the ventral pallidum to process pup stimuli-induced 
afferent input so that voluntary maternal responses can occur. 
Given the linkage between the MPOA and the mesolimbic DA system in 
the control of maternal behavior, it is certainly possible that D1-DA receptor 
activation in MPOA is involved in the activation of efferent projections to VTA, 
which in turn increases D1-DA receptor activation in NA. In the 15HO female that 
is not treated with estradiol, DA activity in both the MPOA and NA may be 
relatively low. By upregulating D1-DA activity in either the MPOA or the NA we 
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circumvent the need for estradiol action on the MPOA and facilitate a rapid onset 
of maternal behavior.
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IV. Study 2: Dopamine D1 receptor activation of adenylyl cyclase, but not 
phospholipase C, in the nucleus accumbens promotes the onset of 
maternal behavior in pregnancy-terminated rats
  The results of study 1 indicate that increased DA action at D1 receptors is 
effective in stimulating the onset of maternal behavior in 15HO rats at the level of 
the NA as well as the MPOA. However, in the context of our neural model, these 
results suggest that DA action at D1 receptors in MPOA results in increased 
activation of MPOA projections to the VTA while DA D1 stimulation of NA results 
in decreased activity of NA output to the VP. An implication of this proposal is that 
distinct inter and/or intracellular mechanisms might mediate DA-D1 effects in 
MPOA and NA. 
 Interestingly, a relatively new body of literature has challenged the classic 
view that D1 receptors are only coupled to cAMP signal cascades. Rather, 
another class of DA D1 receptors exerts its effects by stimulating a different 
signaling cascade, the phospholipase C (PLC) phosphatidylinositol cascade 
which is linked to protein kinase C (PKC; see Figure 2.1.1). This sub-class of DA 
D1 receptors is coupled to a different G protein which stimulates the enzyme PLC 
rather than AC (Clifford et al., 1999; Jin et al., 2001; Undie et al., 2000; Undie 
and Friedman, 1994). The result of PLC stimulation is the hydrolysis of 
phosphatidylinositol biphosphate (PIP2) into diacylglycerol (DAG) and inositol 
triphosphate (IP3). The function of this intracellular signaling cascade is 
increased PKC and intracellular Ca2+. It is unclear at this time what proportion of 
DA D1 receptors are linked to phosphoinositol (PI) signaling, however it appears 
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that PLC linked DA D1 receptors are located on neurons in the hippocampus, 
amygdala, and striatum (Jin et al., 2003; Jin et al., 2001; Ming et al., 2006; 
Wirtshafter and Osborn, 2005). 
  With respect to the findings that microinjection of SKF 38393, a DA D1 
receptor agonist, directly into NA promotes maternal behavior in 15HO rats 
(Stolzenberg et al., 2007) and microinjection of SCH23390, a DA D1 receptor 
antagonist, into NA disrupts ongoing maternal behavior in lactating rats (Numan 
et al., 2005a), note that SKF 38393 is capable of stimulating both signaling 
cascades and SCH 23390 is capable of blocking both pathways (Jin et al., 2003, 
Undie et al., 2000). Therefore, study 2 used two selective pharmacological 
agents: SKF 83959 which is linked to DA D1- PLC (Ming et al., 2006; Jin et al., 
2001, 2003; Undie et al., 2000, Zhen et al., 2005), and SKF 83822 which 
selectively stimulates AC and is not capable of stimulating PLC pathways 
(Kuroiwa et al., 2008; Undie and Friedman, 1994). 
Experiment 2.1.
 Recall that several studies have reported that DA release into the NA 
dampens the effects of excitatory glutamatergic inputs from the limbic system 
and cortex on medium spiny GABA neurons. Electrophysiological data, both in 
vivo and in vitro, also suggest that the inhibitory effect of DA stimulation on NA 
medium spiny neurons is mediated by DA D1 receptors (Calabresi et al., 1987; 
Charara and Grace, 2003; Chergui and Lacey, 1999; Harvey and Lacey, 1996, 
1997; Maeda et al., 2004; Nicola and Malenka, 1997). Whereas DA D1 receptors 
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are frequently associated with the activation of AC, the present experiment was 
aimed at determining whether the facilitatory effect of DA D1 receptor stimulation 
of maternal behavior could be replicated by stimulation of DA D1- PLC receptors 
because of the evidence that these receptors, in particular, are involved in the 
depressive effects of DA D1 stimulation on excitatory postsynaptic potentials in 
NA (Chergui and Lacey, 1999; Harvey and Lacey; Kombian et al., 2003; 
Noriyama et al., 2006).
Methods
The methods of study 2 are the same as those described for the general 
methods section, with a few exceptions. available. Bilateral 22-gauge stainless 
steel guide cannulas were implanted into NA using the DeGroot (1959) 
stereotaxic atlas coordinates: A 9.5, L ± 1.0, V 7.0. The implanted cannulas were 
cemented to the skull with dental acrylic and were occluded with stainless steel 
stylets that extended 2 mm beyond the end of the guide. 
Experiment 2.1 examined the effects of bilateral injections of SKF 83959 
(a DA D1-PLC linked receptor agonist obtained from Sigma, St.Louis, MO) on the 
sensitization latencies of 15HO female rats. Two independent groups of female 
rats received bilateral injections of either 0 µg (Vehicle; n = 7) or 0.5 µg/0.5 µl/
side of SKF 83959 dissolved in sterile water (SKF 83959; n = 8) directly into the 
NA on days 0-2 of behavioral testing. The doses of SKF 83959 were in the range 
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used by other investigators (Adachi et al., 1999; Cools et al., 2002; Hasegawa et 
al., 2001). 
Behavioral observations matched those described in the general methods 
section, except that the first time a female was observed to show full maternal 
behavior (retrieve all 3 pups to a single nest site, lick/groom pups, and hover/
crouch over pups), a detailed 15 minute nursing observation took place. If full 
maternal behavior was observed during the morning one hour test, the 15 minute 
nursing observation occurred from 60-75 min post pup presentation. If maternal 
behavior first occurred during the PM observation, the 15 minute nursing 
observation occurred at that time. Note that regardless of whether the nursing 
observation took place in the morning or in the afternoon, the nursing observation 
always occurred at the first time on the first day the female showed full maternal 
behavior. During the 15 minute nursing observation, a female was observed for 
10-15 seconds every 30 seconds of the 15 minute (for a total of 30 observations), 
and it was noted whether she was hovering, sniffing and licking, or crouching 
over the pups. If a female transitioned from one nursing posture to another, the 
behavior having the longest duration during the interval was recorded. However, 
in most cases the female engaged in only one behavior during each 10-15 
second interval. Females were recorded as hovering when they were upright 
over pups (so that pups had access to the female’s ventral surface) but also 
actively sniffing/licking the pups or engaging in self-grooming. In contrast, 
females were recorded as crouching when in a quiescent, immobile posture, with 
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all four limbs supporting a slightly arched or highly arched posture over the pups 
(Stern and Johnson, 1990). In some cases females also adopted a supine or 
prone position, resting on their side while the pups had access to the female’s 
ventral surface; this posture was recorded as a hover. Incidences of sniffing/
licking were individually noted, but this behavior always occurred while the 
female was in a hover position. Note that this additional nursing observation was 
used to address one question raised by study 1: whether DA D1 agonist treated 
females show a higher quality of maternal behavior than vehicle treated females 
who naturally sensitize. 
Results
Experiment 2.1 examined whether a DA D1-PLC linked receptor agonist 
would stimulate maternal behavior in 15HO rats when injected into the NA. Table 
2.1.1 shows that females receiving SKF 83959 approached and sniffed pups with 
significantly shorter latencies, when averaged on days 0-2; than did the vehicle-
treated females [t(13)= 8.14, p <.01]. However, other aspects of maternal 
behavior did not distinguish the two groups. The median sensitization latency for 
female rats injected with SKF 83959 into the NA (SKF 83959, n = 8) was 6 days 
which was not significantly different from the 5 day median sensitization latency 
shown by vehicle treated females (Vehicle, n = 7; Mann-Whitney U test, U = 24.5, 
p= .6, see Table 2.1.1). The cumulative percentage of females showing full 
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maternal behavior on each test day was similar between the SKF 83959 and 
Vehicle groups (Figure 2.1.2).
Figure 2.1.3. shows reconstructions of the location of the NA injection 
sites, drawn on to the appropriate plates taken from the atlas of Paxinos and 
Watson (1997). Importantly, microscopic analysis of brain sections indicated that 
for each group, all cannula placements were located in the NA, either in the shell 
region or the shell-core border. 
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Table 2.1.1. Outcome Measures for 15HO Female Rats that Received injections 
of SKF 83959 into the Nucleus Accumbens
Table 1. Outcome Measures in 15HO rats that Received injections of SKF 83959 into 
NA or SKF 83822 into NA or VP 
 
 
For each female, latency to approach and sniff pups was averaged across the days of 
testing in which the female was injected with the drug. Therefore, for Experiment 1, 
latency to approach and sniff pups was averaged across days 0-2 of behavioral testing, 
whereas for Experiments 2-3 latency to approach and sniff pups was averaged across 
days 0-1 of behavioral testing. Interquartile ranges are shown in parentheses. 
Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of pregnancy.  
*Significantly different from the Vehicle group, Mann-Whitney U test, p < .05.  
 
 
 
 
 
 
 
 
 
 
Groups N 
Mean ±  SE latency to 
approach-sniff pups (s) 
 
Median onset to full 
maternal behavior (days) 
Experiment 1 
  
hour day 
SKF 83959 8 32.85 (± 13.94)* 6 (2-6) 6 (2-6) 
Vehicle 7 157.42 (± 40.84) 5 (2-6) 6 (2-6) 
Experiment 2 
  
  
SKF 83822 8 225.81 ± 80.03 1 (0-1)* 0 (0-0)* 
Vehicle 10 139 ± 59.73 2.5 (1-6) 2 (0-6) 
Experiment 3 
  
  
SKF 83822 VP 11 186.22 ± 71.73 5 (1-6) 5 (1-6) 
Vehicle VP 11 169.23 ± 64.72 3 (2-6) 3 (1-6) 
For each female, latency to sniff-approach pups was averaged across days of 
drug injection (days 0-2). Interquartile ranges are shown in parentheses. 
Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of 
pregnancy. * Significantly different from the Vehicle group, t test.
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Figure 2.1.1. SKF 83822, a DA D1 receptor agonist that binds exclusively to DA 
D1 receptors that are liked to the stimulatory G protein (Gs) which activates the 
enzyme adenylate cyclase (AC). Once activated, AC catalyzes the conversion of 
ATP to cyclic AMP (cAMP). cAMP binds to the regulatory unit on protein kinase A 
(PKA) inducing a conformational change which exposes the catalytic unit, 
allowing PKA to phosphorylate target proteins. SKF 83959, a DA D1 agonist that 
binds exclusively to DA D1 receptors that are linked to the stimulatory G protein 
Gq which activates the enzyme phospholipase C (PLC). PLC hydrolyzes 
phosphatidylinositol 4,5-biphosphate into diacylglycerol (DAG) and inositol 1,4,5, 
triphosphate (IP3). DAG activates protein kinase C, and IP3 releases intracellular 
calcium stores. 
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Figure 2.1.2. Cumulative percentage of female rats showing full maternal 
behavior on each test day (A) when measured at the end of the test hour or (B) 
when measured at the end of the test day. Females received bilateral 
microinjections of either 0 (Vehicle) or 0.5 (SKF 83959) µg of SKF 83959 (ns= 7, 
8, respectively) into the nucleus accumbens (NA) on days 0, 1, and 2 of testing. 
Groups did not differ significantly.
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Figure 2.1.3. Reconstructions, based on the microscopic analysis of cresyl violet 
stained sections, of the location of SKF 83959 injection sites (black circles = 
0.5µg dose, grey circles= 0 µg dose) into the nucleus accumbens (NA), which 
were drawn onto plates from the Paxinos and Watson (1997) atlas. The numbers 
to the left indicate the distance in millimeters anterior to the interaural plane. All 
implant sites were located on the shell-core border. However, in order to facilitate 
viewing, the depicted locations were spread out slightly to eliminate the overlap 
that actually occurred. 
80
Discussion
 The results of the present experiment indicate that DA action at DA D1-
PLC receptors does not promote the onset of maternal behavior in 15HO rats. It 
is interesting to note that SKF 83959 has been shown to inhibit DA-induced AC 
formation as well as increasing PLC intracellular signaling (Andringa et al., 1999). 
Therefore, the inhibition of DA activation of AC/cAMP may have contributed to 
the lack of effectiveness of SKF 83959, suggesting that activation of AC in NA 
might play an essential in the onset of maternal behavior.
Experiment 2.2.
 The purpose of the present experiment was to examine whether the 
facilitatory effect of SKF 38393, a DA D1 agonist capable of binding to both DA 
D1-PLC and DA D1-AC linked receptors, was mediated by the latter receptor 
subtype. Although several studies have shown that DA D1-PLC receptors are 
associated with neural inhibition in the NA, it is possible that the inhibitory effects 
of DA D1 stimulation of the excitability of medium spiny neurons are mediated by 
DA D1 activation of cAMP and PKA, since some of the motivational effects of D1 
agonist administration to NA appear to be mediated by the AC-cAMP-PKA 
cascade (Lynch and Taylor, 2005).
Method
 Experiment 2.2 examined the effects of bilateral injections of SKF 83822 
(a D1 DA receptor agonist linked to AC obtained from Tocris Bioscience, Ellisville, 
MO) into the NA on the sensitization latencies of 15HO female rats. Two 
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independent groups received either 0 µg (Vehicle; n = 10) or 0.5 µg/0.5 µl/side of 
SKF 83822 (SKF 83822; n = 8) into the medial NA. Each dose of SKF 83822 was 
dissolved in 5% DMSO and sterile H20. The method for this experiment is 
identical to that described for Experiment 2.1 except that female rats were 
injected bilaterally into NA on days 0 and 1 of behavioral testing (rather than on 
days 0-2). It was decided that only injections on days 0 and 1 were needed 
because, based on the data from the previous experiments, these are the days 
on which SKF 38393 exerted its major facilitatory effects on the onset of maternal 
behavior. Because SKF 83959 and SKF 83822 have similar molecular weights, 
the 0.5 µg dose of both drugs is comparable. 
Results
 The results of Experiment 2.2 indicate that the facilitatory effect of DA D1 
receptor activation in the NA on the onset of maternal behavior in 15HO rats is 
mediated DA D1-AC linked receptors which initiate cAMP intracellular signaling. 
Microinjection of SKF 83822, a drug which binds selectively to DA D1 receptors 
linked to AC, directly into the NA of 15HO female rats produced a rapid onset of 
maternal behavior. Females treated with 0.5 µg of SKF 83822 (SKF 83822, n = 
8) on days 0 and 1 of testing showed a median sensitization latency of 1 day, by 
the end of the hour observation, which was significantly shorter than the 2.5 day 
latency of the vehicle treated group (Vehicle, n = 10; Mann-Whitney U test, U = 
17, p < .05; Table 2.2.1). The median sensitization latency for SKF 83822 
females was also significantly shorter than the Vehicle group when measured at 
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the end of the test day: 0 days versus 2 days, respectively (Mann-Whitney U test, 
U = 16.5, p < .05; Table 2.2.1). Importantly, the mean latency to approach and 
sniff pups was not significantly different between SKF 83822 and Vehicle rats, 
indicating that the facilitatory effect of SKF 83822 treatment cannot be the result 
of SKF 83822 treated females approaching pups more readily than vehicle 
treated rats. 
 The cumulative percentage of female rats displaying full maternal behavior 
on each test day is shown in Figure 2.2.1. Microinjection of SKF 83822 directly 
into the NA significantly facilitated the onset of maternal behavior in 15HO rats 
compared vehicle injection. The cumulative percentage of female rats showing 
full maternal behavior was significantly higher in the SKF 83822 group compared 
with Vehicle: 88% versus 30%, respectively, on day 0 of testing when measured 
by the end of the test day (Fig 2.2.1b) and on day 1 of testing when measure by 
the end of the observation hour (Fig 2.2.1a; Fisher exact probability test, p < .05). 
 Statistical comparisons (t-tests) of nursing behavior between SKF 83822 
and Vehicle treated females indicated that no significant differences existed with 
respect to nursing duration, sniffing/licking duration, hover duration, or crouch 
duration over the 15 minute nursing observation (Table 2.2.2). This observation 
occurred for all females on the first observation where full maternal behavior 
occurred. 
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Figure 2.2.2. shows reconstructions of the location of the NA injection 
sites, drawn on to the appropriate plates taken from the atlas of Paxinos and 
Watson (1997). Importantly, microscopic analysis of brain sections indicated that 
for each group, all cannula placements were located in the NA, either in the shell 
region or the shell-core border. 
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Table 2.2.1. Outcome Measures for 15HO rats that Received SKF 83822 
Microinjection into the Nucleus Accumbens
Groups N
Mean ±  SE latency to 
approach-sniff pups (s)
Median onset to full 
maternal behavior 
(days)
hour day
SKF 83822 8 225.81 ± 80.03 1 (0-1)* 0 (0-0)*
Vehicle 10 139 ± 59.73 2.5 (1-6) 2 (0-6)
For each female, latency to sniff and approach pups was averaged across days 
of drug injection (0-1). Interquartile ranges are shown in parentheses. 
Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of 
pregnancy. * Significantly different than Vehicle group, Mann Whitney U test
85
Table 2.2.2. Outcome measures (with standard errors) for Females that Received 
SKF 83822 or Vehicle Microinjections into the Nucleus Accumbens
!
Group N
Mean nursing
duration
Mean no.
sniffs/licks
Mean no.
Hovers
Mean no.
Crouches
SKF 83822 8 25.13 ± 1.72 8.5 ± 2.13 13.88 ± 3.0 9.75 ± 3.13
Vehicle 7 26.57 ± 2.19 7.0 ± 2.82 8.14 ± 3.44 15.29 ± 3.14
Groups did not differ significantly. Note that the number of subjects in each group 
is based on those females that showed maternal behavior during the 5 day test 
period. Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of 
pregnancy.
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Figure 2.2.1. Cumulative percentage of female rats showing full maternal 
behavior on each test day (A.) as measured at the end of the test hour or (B.) as 
measured at the end of the test day. Females received bilateral microinjections of 
either 0 (Vehicle) or 0.5 µg of SKF 83822 (ns= 10, 8, respectively) into the 
nucleus accumbens (NA) on days 0 and 1 of testing. *Significantly different from 
Vehicle, Fisher Exact Probability.
87
Figure 2.2.2. Reconstructions based on the microscopic analysis of cresyl violet 
stained sections, of the location of SKF 83822 injection sites (black circles = 
0.5µg dose, grey circles= 0 µg dose) into the nucleus accumbens (NA), which 
were drawn onto plates from the Paxinos and Watson (1997) atlas. The numbers 
to the left indicate the distance in millimeters anterior to the interaural plane. All 
implant sites were located on the shell-core border. However, in order to facilitate 
viewing, the depicted locations were spread out slightly to eliminate the overlap 
that actually occurred.
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Discussion
The results of the present experiment represent the major finding of study 
2. The facilitatory effect DA activity in NA on the onset of maternal behavior in 
15HO rats is most likely mediated by DA D1-AC receptors and involves 
increased cAMP signaling. Because the facilitatory effect of SKF 83822 
microinjection into NA consistently occurred approximately 5 hours post 
injection(see figure 2.2.1), one possibility is that cAMP intracellular signaling 
cascades promote the onset of maternal behavior via activation of a downstream 
transcription factors which alter gene expression. This hypothesis would be 
consistent with the time course of DA D1-AC receptor stimulation. Importantly, 
activation of the transcription factor cAMP response element binding protein 
(CREB), a downstream target of PKA, in the NA has been associated with the 
initiation of behavioral reactivity toward biological stimuli in naïve animals (Barrot 
et al., 2005), suggesting that activation of cAMP signaling cascades in NA might 
function to increase an organisms responsiveness to pup stimuli during the onset 
of behavior. 
Although the evidence is clear that SKF 83822 activates AC (Kuroiwa et 
al., 2008; Undie and Friedman, 1994), it is possible that this drug also has other 
effects which have yet to be detected, and these effects might have also 
influenced the onset of maternal behavior. Furthermore, since we did not actually 
measure cAMP production, we are going on conclusions from biochemical 
findings of others (Kuroiwa eta l., 2008; Undie and Friedman, 1994). 
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Interestingly, there is some evidence that CREB activity in NA might be 
associated with the onset of male sexual behavior (Barrot et al., 2005). Whereas 
its clear that DA D1 receptor activation is necessary for both the onset 
(Stolzenberg et al., 2007) and maintenance of maternal behavior (Numan et al., 
2005a), activation of CREB might be one downstream signal of DA D1 activation 
which mediates the initial increase in responsiveness necessary to push females 
over the threshold for full maternal behavior.  A good question for future research 
would be whether or not the maintenance of maternal behavior is also dependent 
upon activation of DA D1-AC linked receptors and subsequent stimulation of 
PKA, or whether this intracellular signaling mechanism solely regulates the onset 
of maternal behavior in rats. With respect to the importance of CREB for 
maternal behavior, note that CREB knockout mice show severe deficits in 
maternal behavior (Jin et al., 2005).
The results of Experiment 2.2 also address a question posed by study 1: 
are DA D1 treated females “better” mothers than their sensitized, Vehicle-treated 
counterparts? Therefore, the methods of study 2 included detailed nursing 
observations which were taken for a 15 min period once a female rat had initiated 
maternal behavior. Therefore the exact day and time in which observations were 
taken varied for each rat depending on when they first displayed maternal 
behavior. Comparisons between the duration of nursing behavior, sniffing and 
licking, hovering, and crouching during the 15 min observation revealed no 
significant differences between sensitized Vehicle-treated rats and SKF 83822 
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treated females. These data suggest that SKF 83822 probably functions to 
increase DA action at D1-AC receptors above a particular threshold required for 
the initiation of maternal responsiveness, at which point endogenous DA activity 
probably maintains maternal responsiveness. In this case, it is conceivable that 
sensitized Vehicle-treated rats would display similar amounts of mother-pup 
interaction as SKF 83822-treated females, since endogenous DA is most likely 
involved in the onset of maternal behavior in the vehicle-injected females.  
Experiment 2.3
 While the finding that DA stimulation of DA D1-AC receptors in NA is 
necessary for the DAergic facilitation of maternal behavior in 15HO rats is 
important, this finding is ultimately incomplete without providing evidence that this  
facilitatory effect of SKF 83822 on maternal behavior is not due to spread of the 
injected drug to a nearby region, particularly the MPOA. Because DA action at 
the level of the MPOA also produces facilitatory effects on maternal behavior in 
15HO rats, the present experiment makes use of another region which is located 
in close proximity to both the NA and the MPOA.  In this experiment we 
examined the effects of bilateral application of SKF 83822 to VP. Note that the 
VP is spatially as close to the MPOA as it is to the NA. Our reasoning was that if 
VP injection of SKF 83822 did not facilitate maternal behavior, it would be difficult 
to explain the facilitation of maternal behavior after SKF 83822 application to the 
NA as due to spread to the MPOA.
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Method
The methods for this experiment are identical to those described for 
Experiment 2.1 except that guide cannula were implanted into the ventral 
pallidum (VP) using the DeGroot stereotaxic coordinates: A7.5, L2.5,V5.8. Similar 
to Experiment 2.2, female rats in this experiment received microinjections for 2 
days. Over days 0-1 of behavioral testing, independent groups of 15HO female 
rats received bilateral microinjection of either 0µg (Vehicle VP, n = 11) of SKF 
83822 or 0.5 µg/0.5 µl/ side (SKF 83822 VP, n = 11) dissolved in 5% DMSO in 
sterile water.  
Results
 Female rats injected with SKF 838322 into the VP (SKF 83822 VP; n = 11) 
showed a median sensitization latency of 5 days which was not significantly 
shorter than the 3 day latency shown by vehicle treated rats by the end of the 
hour or the test day (Vehicle; n = 11; Mann-Whitney U test U = 51.5, p = .5114, 
Table 2.3.1). The latency to approach and sniff pups was also not significantly 
different between these two groups of animals (t-test, t(22) = 0.18; Table 2.3.1). 
Figure 2.3.1 indicates that the cumulative percentage of female rats showing full 
maternal behavior on each test day was comparable between SKF 83822 VP 
and Vehicle VP groups. Figure 2.3.2. shows reconstructions of the location of the 
VP injection sites, drawn on to the appropriate plates taken from the atlas of 
Paxinos and Watson (1997). 
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Table 2.3.1. Outcome Measures for 15HO rats that Received SKF 83822 
Microinjection Into the Ventral Pallidum
Groups N
Mean ±  SE latency to 
approach-sniff pups (s)
Median onset to full 
maternal behavior (days)
Experiment 3
SKF 83822 VP 11 186.22 ± 71.73 5 (1-6) 5 (1-6)
Vehicle VP 11 169.23 ± 64.72 3 (2-6) 3 (1-6)
For each female, latency to sniff and approach pups was averaged across drug 
injection days (0-1). Interquartile ranges are shown in parentheses. 
Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of 
pregnancy. Significant differences were not detected.
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hour  day
Figure 2.3.1. Cumulative percentage of female rats showing full maternal 
behavior on each test day, (A) as measured at the end of the test hour or (B) as 
measured at the end of the test day. Females received bilateral microinjections of 
either 0 (Vehicle VP) or 0.5 (SKF 83822 VP) µg of SKF 83959 (ns= 10, 8, 
respectively) into the ventral pallidum (VP) on days 0 and 1 of testing. Groups did 
not differ significantly.
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VP
VP
Figure 2.3.2. Reconstructions based on the microscopic analysis of cresyl violet 
stained sections, of the location of SKF 83822 injection sites (black circles = 
0.5µg dose, grey circles= 0 µg dose) into the ventral pallidum (VP), which were 
drawn onto plates from the Paxinos and Watson (1997) atlas. The numbers to 
the left indicate the distance in millimeters anterior to the interaural plane. 
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Discussion
 The results of Experiment 2.3 are an important contribution to this study, 
and they strongly indicate that the facilitatory effect of SKF 83822 in NA on the 
onset of maternal behavior is localized to the NA, and not due to spread of the 
injected substance to a nearby neural site. It is important to note that the NA is 
not the only neural site where DA D1 receptor stimulation has been found to 
promote the onset of maternal behavior in 15HO rats. For example, DA activity in 
the MPOA also promotes the onset (Experiment 1.1; Stolzenberg et al., 2007). 
The MPOA is a critical hypothalamic nuclei which responds to hormonal and pup 
inputs to regulate maternal responsiveness (Numan and Insel, 2003). One issue 
with examining the effects of DA activity in NA and MPOA is that the MPOA and 
NA are only separated by about 2 mm, therefore it is difficult to know whether 
microinjected substances produced facilitatory effects via spread from one region 
to the other. In the current study, the ventral pallidum (VP) functions as a key 
anatomical control site because (1) it is in close proximity to the MPOA (it is 
located on the same rostro-caudal plane as the MPOA, but roughly 1.5 mm 
lateral to it), (2) it is critical for maternal behavior (Numan et al., 2005b) and (3) it 
also receives DA inputs from the VTA (Klitenick et al., 1992).  
General Discussion
 The present series of experiments made use of two DA D1 receptor 
agonists which have been reported to be selective for the two distinct forms of 
DA D1 receptors. The main finding of the present study is that microinjection of 
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SKF 83822, a DA D1 agonist which selectively binds to DA D1-AC linked 
receptors, directly into NA promotes a rapid onset of maternal behavior in 15HO 
rats, whereas microinjection of SKF 83959, a DA D1 agonist which selectively 
binds to the alternate DA D1-PLC linked receptors, directly into NA is not capable 
of promoting the onset of maternal behavior in 15HO rats. The results of the 
present study replicate our previous work which showed that intra-NA 
microinjection of SKF 38393, a DA D1 receptor agonist which binds both forms of 
the D1 receptor, promotes the onset of maternal behavior in 15HO rats, and 
extend this work by pinpointing the particular intracellular signaling cascade by 
which DA D1 receptor stimulation of NA produces its facilitatory effect on 
maternal behavior. Importantly, the present study also demonstrates that the 
facilitatory effect of SKF 83822 on the stimulation of maternal behavior in 15HO 
rats is not likely to be due to spread of the drug to the MPOA, because 
microinjection of SKF 83822 into the VP did not facilitate the onset of maternal 
behavior in 15HO rats. 
The finding that DA D1-mediated activation of cAMP intracellular signaling 
cascades in NA promotes the onset of maternal behavior in 15HO rats has major 
implications for the intracellular mechanism by which DA produces its facilitatory 
effect. First, whereas a role for the mesolimbic DA system has been well-
established in the regulation of maternal responsiveness, as well as more 
generally in the regulation of behavioral reactivity toward a wide range of 
biologically important stimuli (Numan, 2006), the mechanism by which DA action, 
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particularly at D1 receptors, in NA functions to increase behavioral 
responsiveness is frequently debated (Nicola et al., 2000, Pennartz et al., 1994). 
Therefore, the current data, which indicate that the induction of cAMP signaling 
mediates the facilitatory effects of DA D1 receptor stimulation in NA, provide a 
starting point for investigating how the release of DA into NA functions to 
increase behavioral reactivity. If the Mogenson (1987) model, which seems to 
conform to the data from our laboratory (Numan, 2008), is correct, one can now 
explore the mechanisms through which the D1-AC-cAMP cascade might function 
to reduce the responsiveness of NA to glutamatergic inputs from the limbic 
system.
Secondly, the current work raises the important question of the 
mechanism through which SKF 38393 application to MPOA promotes the onset 
of maternal behavior in 15HO females (Experiment 1.4; Stolzenberg et al., 2007). 
Future work will need to explore the effects of SKF 83822 and SKF 83959 
application to MPOA on the onset of maternal behavior. In other words, does DA 
D1 action at the level of the MPOA stimulate maternal behavior via a PLC or AC 
signaling cascade? Since MPOA output is essential for maternal behavior, while 
it is proposed that NA output might be depressed for maternal behavior to occur, 
it is possible that different signaling cascades are utilized by DA in each region. 
However, if DA action on D1 receptors in MPOA acts on inhibitory interneurons, 
which depress MPOA output, then one can conceive of the possibility that SKF 
83822 might be effective in MPOA , as it is effective in NA (in NA, the proposal is 
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that DA D1 linked to AC is acting on GABAergic output neurons to depress their 
responsiveness. 
Thirdly, the finding that stimulation of NA DA D1 receptor-mediated cAMP 
intracellular signaling promotes the onset of maternal behavior in 15HO rats may 
provide useful information about the mechanism(s) through which estradiol 
regulates maternal responsiveness. Recall that when 15HO females are 
presented with foster pups 48 hours after surgery, they typically show maternal 
behavior after about 2-3 days of exposure. However a rapid onset of maternal 
behavior can be induced in 15HO rats when they are treated with estradiol 
benzoate (EB) at the time of HO surgery (Siegel and Rosenblatt, 1975a). The 
fact that in the absence of EB treatment, 15HO females treated with SKF 38393 
or SKF 83822 directly into the NA could produce a rapid onset of maternal 
behavior, suggests that activation of DA D1 receptors linked to cAMP in NA 
substitutes for the facilitatory effect of estradiol and promotes the onset of 
maternal behavior in 15HO rats (Stolzenberg et al., 2007). Whereas estradiol 
benzoate has been typically administered at the time of HO surgery, 48 hours 
prior to pup presentation, with the assumption that genomic effects of E require 
48 hours to develop, it is certainly possible that EB was acting closer to the time 
of pup presentation, since EB injected in oil may remain in the systemic 
circulation for several days (Numan et al., 1977). Since estradiol action at 
membrane-associated ERs can stimulate the AC/cAMP/PKA cascade (Aronica et 
al., 1994; Razandi et al., 2004; Razandi et al., 1999; Watters and Dorsa, 1998), it 
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is possible that activation of this cascade is one of the common mechanisms 
through which both E and DA stimulate maternal behavior. Study 3 begins an 
examination of this important issue.  
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V. Study 3: A single injection of 17β-estradiol at the time of pup 
presentation promotes the onset of maternal behavior in pregnancy-
terminated rats 
According to our model, the onset of maternal behavior is regulated by the 
hormonal events of pregnancy and parturition. These hormonal events, 
particularly, the rise in estradiol (E) just before birth, probably function to induce 
the onset of maternal behavior through actions at multiple neural sites involved in 
the regulation of maternal behavior. We have focused on the regulation of 
increased maternal responsiveness which is mediated by MPOA interaction with 
the mesolimbic DA system, and therefore I am interested in how E acts on this 
aspect of the neural circuit, in particular. The finding that increased DA action at 
D1 receptors, at the level of the MPOA or the NA, in the absence of appropriate 
E stimulation, promotes the onset of maternal behavior indicates that increased 
DA action at D1-AC receptors might be a downstream effect of E stimulation. In 
support of this idea, recall that subcutaneous injection of estradiol benzoate (EB) 
dissolved in oil at the time of HO, or intra-MPOA implant of EB at the time of HO, 
can reinstate an immediate onset in 15HO rats (Siegel and Rosenblatt, 1975a; 
Numan et al., 1977, respectively). 
If the DA-D1 agonist-treated 15HO rats in studies 1-2 showed a rapid 
onset of maternal behavior because DA D1 receptor stimulation substituted for 
the facilitatory effect of E stimulation, a relevant issue concerns the relationship 
between these two stimulatory effects. Because the long latency and long lasting 
classical effects of hormones are the best documented within the literature, it has 
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often been stated that the immediate activation of responsiveness toward 
biologically significant stimuli by neurotransmitter systems, for example DA, are 
likely influenced by the prior classical genomic effects of hormonal action (Hull et 
al., 1997). In support of this idea, note that EB (both systemic and intra-MPOA) 
has typically been administered at the time of HO surgery, 48 hours prior to pup 
presentation. Treatment with EB at that time was based on the idea that steroid 
hormones exert their effects via the transcription of genes at estrogen responsive 
DNA sites and the subsequent synthesis of new proteins which might take 
several hours to days. However, recall that steroid hormone action also occurs at 
membrane-bound receptors or intracellular receptors and is capable of inducing 
non-classical cellular effects via the activation of intracellular signaling cascades 
and the phosphorylation of proteins (for reviews see Beato and Klug, 2000; 
Bishop and Stormshak, 2008; Bjornstrom and Sjoberg, 2005; Foradori et al., 
2008; Kelly and Levin, 2001; Mhyre and Dorsa, 2006; Toran-Allerand, 2004; 
Vasudevan and Pfaff, 2007, 2008). 
Importantly, the mechanism by which EB produces a facilitatory effect on 
the onset of maternal behavior in 15HO rats is not clear. For example, EB was 
implanted in MPOA at the time of surgery and removed at the time of pup 
presentation (Numan et al., 1977); therefore, the EB implant was still present in 
the MPOA at the time of pup presentation. Further, in 15HO females systemically 
treated with EB at the time of HO, it is also likely that EB was present at the time 
of pup presentation because EB dissolved in oil results in the slow, long-term 
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release of EB from the subcutaneous depot; in confirmation of this idea, vaginal 
cytology of 15HO female rats injected with EB subcutaneously indicates that E is 
exerting cellular effects up to 7 days post injection (Numan, 1978; Numan et al., 
1977). Therefore, the possibility that EB can exert facilitatory effects on maternal 
behavior by acting at the time of pup presentation cannot be ruled out. Since DA-
D1 receptor activation of MPOA or NA at the time of pup presentation stimulates 
maternal behavior, perhaps E and DA operate via similar mechanisms to 
influence the onset of maternal behavior. 
 As a first step to resolving this question, we directly examined whether 
systemic administration of a water-soluble form of 17β-estradiol (E2) can facilitate 
the onset of maternal behavior when injected at the time of pup presentation. 
Note that water-soluble E2 is rapidly absorbed and degraded so that it is 
eliminated within 24 hours of injection (Cross and Roselli, 1999; Taylor, et al., 
1989; Trainor et al., 2008).
Experiment 3.1
Method
The methods used in study 3 were similar to those of study 2, except for 
the following details. In this experiment, females did not undergo stereotaxic 
surgery on day 1 of pregnancy. However, all females were HO on day 15 of 
pregnancy as previously described. 
Female rats in all the experiments of study 3 were administered either 
cyclodextrin encapsulated 17β-estradiol (E2; Sigma cat. # E4389) dissolved in 
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physiological saline or the cyclodextrin/saline vehicle solution. Both solutions, 
once prepared, were stored in the refrigerator and used for up to 5 days.  Female 
rats included in Experiment 3.1 were divided into two independent groups and 
were administered sc 100 µg/kg of E2 (E2 100; n = 9) or vehicle (vehicle; n = 9) on 
days 0 and 1 of behavioral testing, one hour prior to pup presentation.  
Results 
15HO female rats treated with 100 µg/kg of E2 (E2 100, n = 9) on days 0 
and 1 of testing showed a median sensitization latency of 1 day, by the end of the 
hour observation, significantly shorter than the 4 day latency of the vehicle 
treated group (vehicle, n = 9; Mann-Whitney U test, U = 20, p<.05, one-tailed, 
Table 3.1.1). The median sensitization latency for E2 100 females was also 
significantly shorter than vehicle treated animals when measured at the end of 
the test day: 1 day compared with 3 days, respectively (Mann-Whitney U test, U 
= 23, p<.05, one-tailed). 
 The cumulative percentage of female rats displaying full maternal behavior 
by the end of the test hour and by the end of the test day for females in the 
E2100 and vehicle treated conditions is shown in Figure 3.1.1. The cumulative 
percentage of females showing full maternal behavior within the 1 hour morning 
observation period was significantly higher in the E2- treated females on day 3 of 
testing (Fisher exact probability test, p<.05). When the criterion used was the end 
of the test day to show full maternal behavior, the cumulative percentage of 
104
females showing full maternal behavior was significantly higher in the E2- treated 
females on days 2 and 3 of testing (Fisher exact probability test, ps<.05). 
 Statistical comparisons (t-tests) of nursing behavior between E2 100 and 
vehicle treated females indicated that no significant differences existed with 
respect to nursing duration, sniffing/licking duration, hover duration, or crouch 
duration over the 15 minute nursing observation (Table 3.1.2). This observation 
occurred for all females on the first observation where full maternal behavior 
occurred. 
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Table 3.1.1. Outcome Measures for 15HO rats that Received Subcutaneous 
Injections of 17β-estradiol at the time of pup presentation
Median onset to full maternal behavior (days)
Group N Hour Day
E2 100 9 1 (1-1.5)* 1 (0-1)*
Vehicle 9 4 (1-4.5) 3 (0-4)
Interquartile ranges are shown in parentheses. * Significantly different from the 
corresponding vehicle group, Mann-Whitney U test. Female rats were injected 
with either 100 µg/kg of 17β-estradiol (E2 20) or vehicle on days 0-1 of behavioral 
testing. Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of 
pregnancy.
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Table 3.2. Outcome Measures (with standard errors) for 15HO rats that Received 
Subcutaneous Injections of 17β-estradiol at the time of pup presentation
Group N Mean no. sniffs/licks Mean no. Hovers Mean no. Crouches
E2 100 9 10.3 ± 1.6 12.6 ± 1.8 14.2 ± 2.3
Vehicle 8 7.2 ± 2.1 8.7 ± 2.4 20 ± 2.4
E2 100 refers to 100 µg/kg of 17β-estradiol, these female rats were treated with 
estradiol on day 0 of testing one hour prior to pup presentation. * Significantly 
different than vehicle, t-test. Note the number of subjects in each group is based 
on those females that showed maternal behavior during the 5 day test period. 
Abbreviations: 15HO = hysterectomized and ovariectomized on day 15 of 
pregnancy. 
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given at the time of pup presentation. The results of Experiment 2
replicated those of Experiment 1. Female rats treated with a single
injection of E2 (E2 100-single, n=15) showed a signiﬁcantly shorter
sensitization latency than vehicle treated females (vehicle, n=14)
by the end of the observation hour as well as at the end of the test
day (see Table 1). The median sensitization latency for E2 100-single
rats to show full maternal behavior by the end of the observation
hour was 1 day, signiﬁcantly shorter than 3 days displayed by
vehicle treated rats, Mann–Whitney U test, U=65, pb .05, one-
tailed (Table 1). When sensitization latencies were based on the
occurrence of maternal behavior by the end of the test day, the
median sensitization latency for the E2 100-single treated females
(1 day) was signiﬁcantly shorter than the 2.5 day latency observed
in the vehicle-treated females (Mann–Whitney U test, U=60.5,
pb .05, two-tailed).
During the ﬁrst hour on the morning of day 1 of testing, 86.7%
of the E2 100-single females showed full maternal behavior, which
was signiﬁcantly higher than the 28.6% of the vehicle-treated
females showing maternal behavior, and this signiﬁcant differ-
ence between E2 100-single and vehicle-treated rats continued on
day 2 (Fisher exact probability, psb .05, two-tailed; see Fig. 2A).
The cumulative percentage of E2 100 single females showing full
maternal behavior by the end of the test day was also signiﬁcantly
greater than vehicle treated females on days 1 and 2 of testing
(Fisher exact probability test, pb .01, p=.05, two tailed, respec-
tively; see Fig. 2B).
While nursing behavior was relatively similar between E2 100
single and vehicle treated females, a signiﬁcant difference was
detected with respect to crouch duration. Females treated with E2
100 single tended to crouch more frequently over the 15 min
observation than those treated with vehicle [t(23)=1.81, pb .05,
one-tailed; see Table 2].
Fig. 2. (A) Cumulative percentage of female rats showing full maternal behavior by the
end of the hour observation on each test day. (B) Cumulative percentage of female rats
showing full maternal behavior by the end of the day on each test day. Females received
subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100-single) or vehicle
on day 0 of behavioral testing. ⁎Signiﬁcantly different from vehicle group, Fisher exact
probability test.
Table 2
Outcome measures (with standard errors) for 15HO female rats that received
subcutaneous injection of 17β-estradiol.
Experiment Group n Mean no.
sniffs/licks
Mean no.
hovers
Mean no.
crouches
1 E2 100 9 10.3±1.6 12.6±1.8 14.2±2.3
Vehicle 8 7.2±2.1 8.7±2.4 20±2.4
2 E2 100-single 14 8.4±1.3 11.1±1.5 16.7±2.1⁎
Vehicle 12 12.4±2.3 14.9±2.4 10.7±2.4
E2 100 refers to 100 μg/kg of 17β-estradiol, E2 100-single refers to 100 μg/kg of 17β-
estradiol both were treated with estradiol on day 0 of testing only 1 h prior to pup
presentation.
Note the number of subjects in each group is based on those females that showed
maternal behavior during the 5 day test period. Abbreviations: 15HO=hysterectomized
and ovariectomized on day 15 of pregnancy.
⁎ Signiﬁcantly different than vehicle, t-test.
Fig. 1. (A) Cumulative percentage of female rats showing full maternal behavior by the
end of the hour observation on each test day. (B) Cumulative percentage of female rats
showing full maternal behavior by the end of the day on each test day. Females received
subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100) or vehicle on days
0–1 of behavioral testing. ⁎Signiﬁcantly different from vehicle group, Fisher exact
probability test.
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Figure 3.1.1 A. Cumulative percentage of female rats showing full maternal 
behavior by the end of the hour observation on each test day. B. Cumulative 
percentage of f male rats showing full aternal behavior by the end of the day 
on e ch te t day. Females received subcutaneous injections of either 100 µg/kg 
of 17β-estradiol (E2 100) or vehicle on days 0-1 of behavioral testing.
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Discussion
 The purpose of the current experiment was to examine whether 
subcutaneous administration of E2 could replicate that facilitatory effect of SKF 
83822 or SKF 38393 on the onset of maternal behavior in 15HO rats when 
administered at the time of pup presentation. It is already clear that 
subcutaneous administration of EB can replicate the facilitatory effect of SKF 
83822 or SKF 83959 when administered 48 hours prior to pup presentation. The 
injection schedule of E2 in the present experiment was meant mimic the injection 
schedule of SKF 38393 and SKF 83822 in study 1 and study 2, respectively. 
 Whereas subcutaneous administration of E2 promoted the onset of 
maternal behavior in rats, the effect consistently occurred 6-24 hours after 
administration Therefore it appears that while E2 is capable of rapidly promoting 
the onset of maternal behavior, the mechanism by which E2 operates likely 
involves alterations in gene transcription which would be more consistent with a 
6-24 hour onset of maternal behavior.
Experiment 3.2.
 Given that female rats included in Experiment 3.1 tended to show 
maternal behavior on day 1 of testing, the day of the second E2 injection, an 
interesting question is whether an acute injection of E2 on only one day of testing 
would be able to stimulate the onset of maternal behavior 24 hours later. The 
present experiment was conducted to examine this question. It is identical to 
Experiment 3.1 except that females received a single injection of E2  at the time 
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of pup presentation.
Method
Experiment 3.2 consisted of two independent groups of females 
administered sc either 100 µg/kg E2 (E2 100-single; n = 15) or vehicle (vehicle; n 
= 14) in a single injection given on day 0 of behavioral testing, one hour prior to 
pup presentation.
Results
The results of Experiment 3.2 replicated those of Experiment 3.1, 
indicating that a single dose of E2 is sufficient to induce the onset of maternal 
behavior. Female rats in the E2 100-single group (n = 15) showed a significantly 
shorter sensitization latency than vehicle treated females (vehicle, n = 14) by the 
end of the observation hour as well as at the end of the test day (see Table 
3.2.1). The median sensitization latency for E2 100-single rats to show full 
maternal behavior by the end of the observation hour was 1 day, significantly 
shorter than 3 days displayed by vehicle treated rats, Mann-Whitney U test, U = 
65, p<.05, one-tailed (Table 3.2.1). When sensitization latencies were based on 
the occurrence of maternal behavior by the end of the test day, the median 
sensitization latency for the E2 100-single treated females (1 day) was 
significantly shorter than the 2.5 day latency observed in the vehicle-treated 
females (Mann-Whitney U test, U = 60.5, p<.05). 
During the first hour on the morning of day 1 of testing, 86.7% of the E2 
100-single females showed full maternal behavior, which was significantly higher 
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than the 28.6% of the vehicle-treated females showing maternal behavior, and 
this significant difference between E2 100-single and vehicle-treated rats 
continued on day 2 (Fisher exact probability, ps<.05; see Figure 3.2.1A). The 
cumulative percentage of E2 100 single females showing full maternal behavior 
by the end of the test day was also significantly greater than vehicle treated 
females on days 1 and 2 of testing (Fisher exact probability test, p<.01, p = .05, 
respectively; see Figure 3.2.1B). 
 While nursing behavior was relatively similar between E2 100 single and 
vehicle treated females, a significant difference was detected with respect to 
crouch duration. Females treated with E2 100-single tended to crouch more 
frequently over the 15 minute observation than those treated with vehicle [t (23)= 
1.81, p<.05, one-tailed; see Table 3.2.2]. 
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Table 3.2.1. Outcome Measures for 15HO rats that Received Subcutaneous 
Injection of 17β-estradiol at the time of pup presentation
Median onset to full maternal behavior (days)
Group N Hour Day
E2 100-single 15 1 (1-1)* 1 (0-1)*
Vehicle 14 3 (1-3) 2.5 (0-3)
Interquartile ranges are shown in parentheses. * Significantly different from the 
corresponding vehicle group, Mann-Whitney U test. Females were injected with 
either 100 μg/kg of 17β-estradiol (E2 100-single) or vehicle on day 0 of 
behavioral testing. Abbreviations: 15HO = hysterectomized and ovariectomized 
on day 15 of pregnancy.
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Table 3.2.2. Outcome Measures (with standard errors) for 15HO rats that 
Received Subcutaneous Injection of 17β-estradiol at the time of pup presentation
Group N Mean no. sniffs/licks
Mean no. 
Hovers Mean no. Crouches
E2 100-single 14 8.4 ± 1.3 11.1 ± 1.5 16.7 ± 2.1*
Vehicle 12 12.4 ± 2.3 14.9 ± 2.4 10.7 ± 2.4
E2 100-single refers to 100 μg/kg of 17β-estradiol and Vehicle refers to vehicle 
injected females. Females were treated with estradiol on day 0 of testing only 
one hour prior to pup presentation. * Significantly different than vehicle, t-test. 
Note the number of subjects in each group is based on those females that 
showed maternal behavior during the 5 day test period. Abbreviations: 15HO = 
hysterectomized and ovariectomized on day 15 of pregnancy. 
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given at the time of pup presentation. The results of Experiment 2
replicated those of Experiment 1. Female rats treated with a single
injection of E2 (E2 100-single, n=15) showed a signiﬁcantly shorter
sensitization latency than vehicle treated females (vehicle, n=14)
by the end of the observation hour as well as at the end of the test
day (see Table 1). The median sensitization latency for E2 100-single
rats to show full maternal behavior by the end of the observation
hour was 1 day, signiﬁcantly shorter than 3 days displayed by
vehicle treated rats, Mann–Whitney U test, U=65, pb .05, one-
tailed (Table 1). When sensitization latencies were based on the
occurrence of maternal behavior by the end of the test day, the
median sensitization latency for the E2 100-single treated females
(1 day) was signiﬁcantly shorter than the 2.5 day latency observed
in the vehicle-treated females (Mann–Whitney U test, U=60.5,
pb .05, two-tailed).
During the ﬁrst hour on the morning of day 1 of testing, 86.7%
of the E2 100-single females showed full maternal behavior, which
was signiﬁcantly higher than the 28.6% of the vehicle-treated
females showing maternal behavior, and this signiﬁcant differ-
ence between E2 100-single and vehicle-treated rats continued on
day 2 (Fisher exact probability, psb .05, two-tailed; see Fig. 2A).
The cumulative percentage of E2 100 single females showing full
maternal behavior by the end of the test day was also signiﬁcantly
greater than vehicle treated females on days 1 and 2 of testing
(Fisher exact probability test, pb .01, p=.05, two tailed, respec-
tively; see Fig. 2B).
While nursing behavior was relatively similar between E2 100
single and vehicle treated females, a signiﬁcant difference was
detected with respect to crouch duration. Females treated with E2
100 single tended to crouch more frequently over the 15 min
observation than those treated with vehicle [t(23)=1.81, pb .05,
one-tailed; see Table 2].
Fig. 2. (A) Cumulative percentage of female rats showing full maternal behavior by the
end of the hour observation on each test day. (B) Cumulative percentage of female rats
showing full maternal behavior by the end of the day on each test day. Females received
subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100-single) or vehicle
on day 0 of behavioral testing. ⁎Signiﬁcantly different from vehicle group, Fisher exact
probability test.
Table 2
Outcome measures (with standard errors) for 15HO female rats that received
subcutaneous injection of 17β-estradiol.
Experiment Group n Mean no.
sniffs/licks
Mean no.
hovers
Mean no.
crouches
1 E2 100 9 10.3±1.6 12.6±1.8 14.2±2.3
Vehicle 8 7.2±2.1 8.7±2.4 20±2.4
2 E2 100-single 14 8.4±1.3 11.1±1.5 16.7±2.1⁎
Vehicle 12 12.4±2.3 14.9±2.4 10.7±2.4
E2 100 refers to 100 μg/kg of 17β-estradiol, E2 100-single refers to 100 μg/kg of 17β-
estradiol both were treated with estradiol on day 0 of testing only 1 h prior to pup
presentation.
Note the number of subjects in each group is based on those females that showed
maternal behavior during the 5 day test period. Abbreviations: 15HO=hysterectomized
and ovariectomized on day 15 of pregnancy.
⁎ Signiﬁcantly different than vehicle, t-test.
Fig. 1. (A) Cumulative percentage of female rats showing full maternal behavior by the
end of the hour observation on each test day. (B) Cumulative percentage of female rats
showing full maternal behavior by the end of the day on each test day. Females received
subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100) or vehicle on days
0–1 of behavioral testing. ⁎Signiﬁcantly different from vehicle group, Fisher exact
probability test.
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Figure 3.2.1. A. Cumulative percentage of female rats showing full maternal 
behavior by the end of the hour observation on each test day. B. Cumulative 
percentage of f male rats showing full aternal behavior by the end of the day 
on each test day. Females received subcutaneous injections of either 100 µg/kg 
of 17β-estradiol (E2 100-single) or vehicle on day 0 of behavioral testing. 
*Significantly different from vehicle group, Fisher exact probability test.
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Discussion
 In summary, the above results replicated those of Experiment 3.1 and 
indicated that a second injection of E2 is not necessary to produce facilitatory 
effects on the onset of maternal behavior in 15HO rats. Note that the results from 
Experiments 3.1 and 3.2 indicate that the major facilitatory effect of E2 treatment 
occurred by the morning of day 1, which means that prior to the start of maternal 
behavior testing on day 1, when the experimenter removed the pups from the 
previous day, almost all females treated with E2 were already showing maternal 
behavior. However because maternal behavior observations are not taken 
between 5 PM and 9 AM, the exact time of maternal behavior onset is not clear. 
That is, the facilitatory effect of E2 treatment occurred sometime between 
between 6-24 hours after injection, but whether it occurred at 6 hours, 12 hours, 
or 24 hours is not clear. 
Experiment 3.3
Method
 Experiment 3.3 consisted of two independent groups of females 
administered sc either 100 µg/kg E2 (E2 100 day 15; n = 12) or vehicle (vehicle; n 
= 13) at the time of HO surgery, 48 hours before day 0 of behavioral testing. 
Results
Experiment 3.3 examined whether water-soluble E2 is capable of 
facilitating maternal behavior when injected at the time of HO, on day 15 of 
pregnancy. The results indicated that 100 µg/kg of E2, a dose that initiated 
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maternal responsiveness in 15HO females when administered at the time of pup 
presentation, was not capable of facilitating maternal behavior when injected at 
the time of HO. The median sensitization latency measured by the test hour for 
E2-treated females (E2 100 day 15, n = 12) was 3 days, and this latency was 2.5 
days when measured at the end of the test day, both of which were similar to the 
2 day median sensitization latencies shown by vehicle-treated females (vehicle, n 
= 13) in the hour and in the day (Table 3.3.1). Figure 3.3.1 shows that the 
cumulative percentage of females showing full maternal behavior on each test 
day was similar for E2- and vehicle-treated females. 
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Table 3.3.1. Outcome Measures for 15HO rats that Received Subcutaneous 
Injection of 17β-estradiol at the time of pup presentation
Median onset to full maternal behavior (days)
Group N Hour Day
E2 100 day 15 12 3 (1-6) 2.5 (0-6)
Vehicle 13 2 (0.5-5.5) 2 (0.5-5)
Interquartile ranges are shown in parentheses. Females were injected with either 
100 μg/kg of 17β-estradiol (E2 100) or vehicle on day 15 of pregnancy at the time 
of surgery.  Abbreviations: 15HO = hysterectomized and ovariectomized on day 
15 of pregnancy.
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Experiment 3
Experiment 3 examined whether water-soluble E2 is capable of
facilitating maternal behavior when injected at the time of HO, on day
15 of pregnancy. The results indicated that 100 μg/kg of E2, a dose that
initiatedmaternal responsiveness in 15HO femaleswhen administered
at the time of pup presentation, was not capable of facilitating
maternal behavior when injected at the time of HO. The median
sensitization latency measured by the test hour for E2-treated females
(E2 100 day 15, n=12) was 3 days, and this latency was 2.5 days when
measured at the end of the test day, both of which were similar to the
2 daymedian sensitization latencies shown by vehicle-treated females
(vehicle, n=13) in the hour and in the day (Table 1). Fig. 3 shows that
the cumulative percentage of females showing full maternal behavior
on each test day was similar for E2- and vehicle-treated females.
Experiment 4
Experiment 4 examined whether a single subcutaneous injection
of E2 (100 μg/kg) administered 1 hour prior to pup presentation on
day 0 of behavioral testing would facilitate the onset of maternal
behavior in HO virgin female rats. HO virgin female rats treated with
E2 (E2 100-virgin, n=10) showed similar sensitization latencies as did
vehicle-treated virgin females (vehicle, n=10); the median sensitiza-
tion latency for E2 100-virgin females was 6 days, which was not
signiﬁcantly different from the 6 day median sensitization latency
displayed by vehicle injected rats (Table 1). Fig. 4 shows that virgin
female rats did not show any facilitation of maternal behavior onset in
response to E2 treatment.
Discussion
A novel and major ﬁnding of this study is that E2 treatment at the
time of pup presentation can facilitate the onset of maternal behavior
in 15HO rats. Importantly, the facilitatory effect of E2 occurs in
response to a single acute injection because the results of Experiment
2 demonstrate that a second injection of E2 is not necessary to produce
the facilitatory effects observed in Experiment 1, where E2 was
injected on days 0 and 1 of behavioral testing. The fact that 100 μg/kg
of water-soluble E2 was not able to stimulate maternal behavior when
injected on day 15 of pregnancy, at the time of HO, indicates that E2
needs to act closer to the time of pup presentation in 15HO females to
produce a facilitatory effect on maternal behavior. Finally, the data
from Experiment 4 indicate a 100 μg/kg E2 injection does not produce
a facilitatory effect in HO virgin female rats, supporting the view that
the facilitation of maternal behavior by an acute injection of E2 is
dependent upon the priming effects of prior exposure to the
endocrine events of 15 days of pregnancy plus the endocrine events
produced by pregnancy termination. These priming factors are likely
to include lactogenic hormones, P withdrawal, and minimal E
stimulation (Numan and Insel, 2003).
While E2 treatment produced a facilitation of maternal behavior in
Experiments 1–2, the major stimulatory effect consistently occurred
after the ﬁrst day of pup exposure. Therefore, while some females
showed an immediate onset of maternal behavior on day 0 of testing,
the majority of females receiving E2 injections were observed to be
Fig. 4. (A) Cumulative percentage of virgin female rats showing full maternal behavior
by the end of the hour observation on each test day. (B) Cumulative percentage of
female rats showing full maternal behavior by the end of the day on each test day.
Females received subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100-
virgin) or vehicle on day 0 of behavioral testing.
Fig. 3. (A) Cumulative percentage of female rats showing full maternal behavior by the
end of the hour observation on each test day. (B) Cumulative percentage of female rats
showing full maternal behavior by the end of the day on each test day. Females received
subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100 day 15) or vehicle
on day 15 of pregnancy just after hysterectomy-ovariectomy surgery, 48 h before pup
presentation.
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Figure 3.3.1. A. Cumulative percentage of female rats showing full maternal 
beh vi r by the end of the hour observ ti n on each test day. B. Cumulative 
percentag  of female rats showing full maternal behavior by the end of the day 
on each test day. Females received subcutaneous injections of either 100 µg/kg 
of 17β-estradiol (E2 100 day 15) or vehicle on day 15 of pregnancy just after 
hysterectomy-ovariectomy surgery, 48 hours before pup presentation.
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Discussion
The fact that 100 µg/kg of water-soluble E2 was not able to stimulate 
maternal behavior when injected on day 15 of pregnancy, at the time of HO, 
indicates that E2 needs to act closer to the time of pup presentation in 15HO 
females to produce a facilitatory effect on maternal behavior. The major 
implication of this finding is that the facilitatory effects observed after EB in oil 
administration systemically on day 15, or directly into the MPOA, are probably 
not due to a genomic effect which occurred over the 48 hour period of time 
between EB administration and pup presentation. Instead, the current data 
indicate that some of the stimulatory effects of estradiol on maternal behavior, 
whether genomic or nongenomic, occur closer to the time of pup presentation 
than previously determined. Because the water-soluble E2 preparation is quickly 
metabolized, any effects initiated by the injection of E2 in saline/cyclodextrin on 
day 15, post HO, are no longer capable of stimulating maternal behavior 48 
hours later, at the time of pup presentation.
Experiment 3.4.
Method
Experiment 3.4 consisted of two independent groups of HO virgin female 
rats administered sc 100 µg/kg E2 (E2 100 virgin; n = 10) or vehicle (vehicle; n = 
10) on day 0 of behavioral testing, one hour prior to pup presentation. Note that 
the the methods for Experiment 3.4 are identical to that of 3.1-3.2, except that 
virgin females were not mated, and these females were transferred to test cages 
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24 hours prior to HO. Pups were presented to these females, as previously 
described, 48 hours post-HO.
Results
 Experiment 3.4 examined whether a single subcutaneous injection of E2 
(100 µg/kg) administered one hour prior to pup presentation on day 0 of 
behavioral testing would facilitate the onset of maternal behavior in HO virgin 
female rats. HO virgin female rats treated with E2 (E2 100-virgin, n = 10) showed 
similar sensitization latencies as did vehicle-treated virgin females (vehicle, n = 
10); the median sensitization latency for E2 100-virgin females was 6 days, which 
was not significantly different from the 6 day median sensitization latency 
displayed by vehicle injected rats (Table 3.4.1). Figure 3.4.1 shows that virgin 
female rats did not show any facilitation of maternal behavior onset in response 
to E2 treatment. 
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Table 3.4.1. Outcome Measures for 15HO rats that Received Subcutaneous 
Injection of 17β-estradiol at the time of pup presentation
Median onset to full maternal behavior (days)
Group N Hour Day
E2 100-virgin 10 6 (4-6) 6 (4-6)
Vehicle 10 6 (6-6) 6 (6-6)
Interquartile ranges are shown in parentheses. Virgin females were 
hysterectomized and ovariectomized and injected with either 100 μg/kg of 17β-
estradiol (E2 100) or vehicle on day 0 of behavioral testing. Abbreviations: 15HO 
= hysterectomized and ovariectomized on day 15 of pregnancy.
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Experiment 3
Experiment 3 examined whether water-soluble E2 is capable of
facilitating maternal behavior when injected at the time of HO, on day
15 of pregnancy. The results indicated that 100 μg/kg of E2, a dose that
initiatedmaternal responsiveness in 15HO femaleswhen administered
at the time of pup presentation, was not capable of facilitating
maternal behavior when injected at the time of HO. The median
sensitization latency measured by the test hour for E2-treated females
(E2 100 day 15, n=12) was 3 days, and this latency was 2.5 days when
measured at the end of the test day, both of which were similar to the
2 daymedian sensitization latencies shown by vehicle-treated females
(vehicle, n=13) in the hour and in the day (Table 1). Fig. 3 shows that
the cumulative percentage of females showing full maternal behavior
on each test day was similar for E2- and vehicle-treated females.
Experiment 4
Experiment 4 examined whether a single subcutaneous injection
of E2 (100 μg/kg) administered 1 hour prior to pup presentation on
day 0 of behavioral testing would facilitate the onset of maternal
behavior in HO virgin female rats. HO virgin female rats treated with
E2 (E2 100-virgin, n=10) showed similar sensitization latencies as did
vehicle-treated virgin females (vehicle, n=10); the median sensitiza-
tion latency for E2 100-virgin females was 6 days, which was not
signiﬁcantly different from the 6 day median sensitization latency
displayed by vehicle injected rats (Table 1). Fig. 4 shows that virgin
female rats did not show any facilitation of maternal behavior onset in
response to E2 treatment.
Discussion
A novel and major ﬁnding of this study is that E2 treatment at the
time of pup presentation can facilitate the onset of maternal behavior
in 15HO rats. Importantly, the facilitatory effect of E2 occurs in
response to a single acute injection because the results of Experiment
2 demonstrate that a second injection of E2 is not necessary to produce
the facilitatory effects observed in Experiment 1, where E2 was
injected on days 0 and 1 of behavioral testing. The fact that 100 μg/kg
of water-soluble E2 was not able to stimulate maternal behavior when
injected on day 15 of pregnancy, at the time of HO, indicates that E2
needs to act closer to the time of pup presentation in 15HO females to
produce a facilitatory effect on maternal behavior. Finally, the data
from Experiment 4 indicate a 100 μg/kg E2 injection does not produce
a facilitatory effect in HO virgin female rats, supporting the view that
the facilitation of maternal behavior by an acute injection of E2 is
dependent upon the priming effects of prior exposure to the
endocrine events of 15 days of pregnancy plus the endocrine events
produced by pregnancy termination. These priming factors are likely
to include lactogenic hormones, P withdrawal, and minimal E
stimulation (Numan and Insel, 2003).
While E2 treatment produced a facilitation of maternal behavior in
Experiments 1–2, the major stimulatory effect consistently occurred
after the ﬁrst day of pup exposure. Therefore, while some females
showed an immediate onset of maternal behavior on day 0 of testing,
the majority of females receiving E2 injections were observed to be
Fig. 4. (A) Cumulative percentage of virgin female rats showing full maternal behavior
by the end of the hour observation on each test day. (B) Cumulative percentage of
female rats showing full maternal behavior by the end of the day on each test day.
Females received subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100-
virgin) or vehicle on day 0 of behavioral testing.
Fig. 3. (A) Cumulative percentage of female rats showing full maternal behavior by the
end of the hour observation on each test day. (B) Cumulative percentage of female rats
showing full maternal behavior by the end of the day on each test day. Females received
subcutaneous injections of either 100 μg/kg of 17β-estradiol (E2 100 day 15) or vehicle
on day 15 of pregnancy just after hysterectomy-ovariectomy surgery, 48 h before pup
presentation.
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Figure 3.4.1. A. Cumulative percentage of virgin female rats showing full 
maternal behavior by the end of the hour observation on each test day. B. 
Cumulative percentage of female rats showing full maternal behavior by the end 
of the day on each test day. Females received subcutaneous injections of either 
100 µg/kg of 17β-estradiol (E2 100-virgin) or vehicle on day 0 of behavioral 
testing.
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Discussion
Experiment 3.4 indicates that a 100 µg/kg E2 injection does not produce a 
facilitatory effect in HO virgin female rats, supporting the view that the facilitation 
of maternal behavior by an acute injection of E2 is dependent upon the priming 
effects of prior exposure to the endocrine events of 15 days of pregnancy plus 
the endocrine events produced by pregnancy termination. These priming factors 
are likely to include lactogenic hormones, P withdrawal, and minimal E 
stimulation (Numan and Insel, 2003). The data of this experiment clearly indicate 
that the females in both groups behaved like typical naive virgin female rats, with 
sensitization latencies greater than 5 days. Indeed, most females were not 
maternal over the 5-day test period. 
General Discussion
 The major finding of this study is that E2 injection at the time of pup 
presentation induces a rapid onset of maternal behavior. Note that while females 
rapidly sensitize, almost all E2-treated rats showed a sensitization latency of day 
1, indicating that the facilitatory effect of E2 occurs between 6-24 hours after 
injection. This finding should be contrasted with the fact that when EB in oil is 
injected sc on day 15 post HO, most females show maternal behavior on day 0 of 
testing, 48 hours later (Siegel and Rosenblatt, 1975a, 1975b; Rosenblatt et al., 
1998). Therefore, the following facts need to be integrated: (1) EB in oil injected 
on day 15 stimulates maternal behavior when pups are presented 48 hours later, 
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with females showing a median sensitization latency of 0 days, (2) E2 in saline/
cyclodextrin injected on day 15 does not stimulate maternal behavior when pups 
are presented 48 hours later, and (3) E2 in saline/cyclodextrin injected at the time 
of pup presentation results in a median sensitization latency of about 1 day. One 
interpretation, based on the putative degradation pattern of EB in oil compared 
with E2 in saline/cyclodextrin, is that E2 must act several hours (6-24 hours) 
before pup stimuli can elicit maternal responsiveness, and such an interpretation 
would be consistent with the idea that E2 stimulates maternal behavior by 
exerting classical or non-classical genomic effects. Importantly, the current data 
indicate that the stimulatory effects of estradiol on maternal behavior occur closer 
to the time of pup presentation than previously determined, because any 
genomic effects initiated by the injection of E2 in saline/cyclodextrin on day 15, 
post HO, are no longer capable of stimulating maternal behavior 48 hours later, 
at the time of pup presentation. Therefore, EB in oil probably produced its 
facilitatory effect on maternal behavior by acting in the last 6-24 hours (rather 
than 48 hours) prior to pup presentation, and also possibly at the time of pup 
presentation. Therefore, an alternate interpretation of the finding that both 
systemic and intra-MPOA EB stimulation produced an immediate onset of 
maternal behavior after 48 hours of EB stimulation (Numan et al., 1977; Siegel 
and Rosenblatt 1975a, 1975b) is that EB exerted its effects 6-24 hours prior to 
pup presentation, and that both classical and non-classical mechanisms of E2 
action might contribute to the onset of maternal behavior. Finally, it should be 
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emphasized that since the injection of E2 facilitated the onset of maternal 
behavior when administered at the time of pup presentation were systemic 
injections, the actual neural site at which E2 acted in this type of preparation 
needs to be explored in future work. 
VI. Concluding Discussion
 The focus of this paper has been on understanding the neural 
mechanisms which govern the natural change in maternal responsiveness 
female rats show at birth, which we have defined as maternal motivation. The 
hormonal events of pregnancy and parturition act on key neural sites which 
regulate maternal responsiveness, altering cellular activity to allow infant stimuli 
access to the neural circuitry which regulates maternal behavior. Importantly, 
while I have emphasized the role of neurotransmitter/neuromodulators in 
maternal motivation, particularly the role of mesolimbic DA system, the rise in E 
at parturition also plays an integral role in maternal motivation. Therefore, I have 
also investigated the hormonal mediation of the onset of maternal behavior. One 
objective of this thesis has been to understand the interaction between hormone 
action and the mesolimbic DA system with respect to maternal motivation. 
Importantly, knowledge about how hormones interact with neurotransmitter 
systems in the brain so that behavioral responsiveness remains intact long after 
the hormonal events have waned may have broader implications for 
understanding how, in certain species, the brain has evolved to become less 
125
dependent on hormonal stimulation even when initially processing and 
responding to infant stimuli. 
 This dissertation was comprised of 3 major aims. First, the hypothesis that 
increased DA activity in the NA can facilitate the onset maternal behavior in naive 
rats was evaluated. Importantly, while several researchers have made this claim, 
prior to study 1 there was no direct empirical support for it. Because the 
hypothalamic DA system may also be involved in the regulation of established 
maternal behavior (Miller and Lonstein, 2005; Numan et al., 2005a), the role of 
DA input to the MPOA on the onset of maternal behavior was also evaluated.  
The results of the study 1 provided the first evidence that increased DA action at 
D1 receptors in either the MPOA or the NA promotes the onset of maternal 
behavior in sub-optimally hormone-primed rats. Second, because the cellular 
mechanism by which DA release into NA and its subsequent action at D1 
receptors functions to increase behavioral reactivity is often debated, the 
intracellular signaling cascade which mediates the facilitatory effect of DA D1 
receptor activation on increased maternal responsiveness was evaluated. The 
results of study 2 provide important implications with respect to the mechanism 
by which DA D1 receptor activation might modulate increased behavioral 
reactivity. Third, the combined results of study 1 and study 2 have indicated that 
in the absence of E, DA stimulation of the NA or the MPOA is capable of inducing 
the onset of maternal behavior in 15HO rats. These findings have been 
interpreted to mean that DA D1 receptor activation is capable of substituting for 
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E. Therefore, study 3 was undertaken to gain more information about the nature 
of the relationship between E and DA. For example, several possibilities exist: (1) 
Does DA substitute for E because increased DA D1 activation is a downstream 
effect of E stimulation? (2) Does DA D1 activation substitute for E because they 
are both capable of initiating maternal behavior via the same intracellular 
signaling cascades, and are therefore interchangeable? (3) Does DA D1 
activation substitute for E because activation of intracellular kinases culminates 
in the phosphorylation of ER, and therefore, DA can activate ER similar to E itself 
(Gangolli et al.,1997; Olesen et al., 2005; Olesen et al., 2007; Olesen et al., 
2008). The results of study 3, therefore, are an important complement to studies 
1-2, and have important implications with respect to which of these possibilities is 
most conceivable. 
 Taken together, the major findings of these 3 studies indicate that DA D1 
stimulation of NA or MPOA produces similar facilitatory effects as systemic E2 
administration on the onset of maternal behavior in 15HO rats. Because all three 
manipulations were capable of promoting the onset of maternal behavior within 
24 hours of injection, the hypothesis that DA D1 receptor stimulation substitutes 
for E because each compound uses a similar mechanism of action (possibility 
#2) is plausible. Additionally, because DA D1 agonist application to MPOA or NA 
produce a more rapid (albeit slight) effect on the onset of maternal behavior in 
15HO rats when compared to E2 injection at the time of pup presentation, the 
possibility that DA D1 receptor activation is upstream from ER stimulation 
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(possibility #3) is unlikely; however, the possibility that DA D1 receptor activation 
is downstream from ER activation is still feasible (possibility #1).
 Before I address the important implications of the studies contained 
herein, a brief review of our hypothetical model of the neural circuitry regulating 
maternal responsiveness will add the necessary context to this discussion (note 
that evidence for this model is referenced in the Introduction and a schematic is 
depicted in Figure I). We have proposed that the MPOA regulates increased 
maternal responsiveness through its efferent projections to the VTA. These 
projections allow MPOA output to activate the release of DA into the NA. The NA-
VP circuit regulates increased behavioral responsiveness toward a wide range of 
biologically salient stimuli, and which stimuli are responded to in particular 
depends on which stimuli elicit DA release into this system at a given time. For 
example, in the absence of DA release, pup inputs to the NA-VP circuit are 
unlikely to elicit maternal responsiveness because NA projections to the VP are 
inhibitory. When the MPOA has been appropriately primed by hormones, pup 
inputs act on the MPOA, increasing output of MPOA neurons to the VTA and 
activating DA release into NA. The release of DA into NA is proposed to depress 
the activity of NA output neurons, thereby releasing the VP from inhibition and 
allowing it to respond to pup inputs with increased maternal responsiveness. 
 In the context of this model, we have argued that in naturally parturient 
female rats, the hormonal events of pregnancy and parturition act on the MPOA 
to increase output of MPOA neurons which project to the VTA in the presence of 
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pup inputs (see Figure VI). The resultant increased release of DA into NA 
mediates the immediate onset of maternal behavior that parturient females 
naturally show at birth. In the 15HO sub-optimally hormone-primed rat, MPOA 
neurons do not strongly activate the VTA in response to pup inputs, and therefore 
the resultant DA release into NA is not enough to activate maternal 
responsiveness. The results of study 1 and study 2 suggest that SKF 38393 and 
SKF 83822 microinjection into NA circumvents the need for hormonal mediation 
by artificially increasing DA action at DA D1-AC receptors. The results of study 1 
suggest that SKF 38393 microinjection (which activates both DA D1-AC and DA 
D1-PLC receptors) into MPOA circumvents the need for hormonal mediation by 
increasing the output of MPOA neurons which project to the VTA and therefore 
the resultant DA release into NA is sufficient to induce maternal responsiveness. 
The results of study 3 indicate that the mechanism by which E2 acts on this 
neural system to facilitate maternal behavior might include a nonclassical 
component, and therefore it is possible that in addition to indirectly facilitating DA 
release in NA (through an action on MPOA), E2 might also act at the level of the 
NA to potentiate DA action directly. Furthermore, at the level of the MPOA, E2 
and DA D1 action may stimulate maternal behavior onset by affecting similar 
intracellular signaling cascades.
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Figure VI. Hypothetical model adapted from Numan and Stolzenberg, (2009). 
Naturally parturient females immediately respond to infant stimuli because the 
hormone-primed medial preoptic area (MPOA) responds to pups with increased 
activation of the ventral tegmental area (VTA) and the subsequent release of 
dopamine (DA) into the nucleus accumbens (NA) promotes the onset of maternal 
behavior. When a naive female rat is partly hormone primed (such as the 15HO 
female) the MPOA weakly activates the VTA and therefore a sub-threshold 
amount of DA is released into NA, and maternal behavior onset is delayed 2-3 
days. However, the effects of hormone action on the MPOA can be circumvented 
via artificial increase of DA activity at D1 receptors (either by injection of SKF 
38393 or SKF 83822) in NA of partly-primed females and this manipulation 
increases DA activity to threshold amounts and initiates a rapid onset of maternal 
behavior. Note that microinjection of SKF 38393 directly into the MPOA also 
circumvents the need for hormone stimulation, presumably by increasing MPOA 
activation of the VTA and thereby indirectly increasing DA release into the NA 
(this is not shown here).
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 The results of this thesis suggest that DA D1 stimulation of either the 
medial NA or the MPOA is capable of substituting for E in the stimulation of 
maternal behavior onset in 15HO females either because DA D1 activity is 
downstream from E2 effects or because DA D1 activity and E2 stimulation operate 
via similar underlying mechanisms. At the present time, we do not know which of 
these potential mechanisms, which are not mutually exclusive, are actually 
operative. In the discussion which follows, I will present examples which lend 
support to each type of mechanism of action at both the level of the NA and the 
MPOA. 
 Because DA D1 receptor stimulation of the MPOA or direct EB stimulation 
of the MPOA have both been found to facilitate a rapid onset of maternal 
behavior, is there any evidence that a downstream effect of E stimulation in 
MPOA is related to a potentiation of DA activity? Elaine Hull and colleagues have 
uncovered a mechanism by which the classical genomic actions of E in MPOA 
potentiate the release of DA in the MPOA which is critical for the display of male 
sexual behavior in rats (Hull and Dominguez, 2006).  First, recall that the neural 
circuitry regulating male sexual behavior in rats is very similar to the neural 
circuitry regulating maternal behavior (Numan, 1974, 1985). Importantly, E and 
DA have both been found to act in the MPOA to stimulate male sexual behavior 
(reviewed in Hull and Domiguez, 2006), and I have reviewed the evidence that 
similar mechanisms operate for maternal behavior. While some sexual 
dimorphism exists within the MPOA, it is possible that some of the mechanisms 
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which regulate maternal behavior and male sexual behavior are similar. 
Therefore, the Hull and Dominguez (2006) work on male sexual behavior may 
apply to maternal behavior. They report that NO is one link between E and DA 
action in the MPOA which regulates male sexual behavior. The classic genomic 
mechanism by which the E-ER complex influences DA activity is through 
increased transcription of nitric oxide synthase (NOS), which is necessary for the 
production of NO (Putnam et al., 2005). Once produced, NO potentiates DA 
activity (Dominguez et al., 2004; West et al., 2002). Therefore, the effects of DA 
on male sexual behavior in the MPOA are downstream from the effects of E2. 
While this idea has been best developed in the male sexual behavior literature 
(Hull and Dominguez, 2006), note that disruption of NO production in the MPOA 
has been found to disrupt maternal behavior (Service and Woodside, 2007), and 
interestingly, SKF 38393 injection into MPOA can reverse these deleterious 
effects on maternal behavior (Service and Woodside, 2006).
 Whereas a role of E potentiation of DA effects has been worked out at the 
level of the MPOA, there is less evidence for this idea with respect to the NA. 
Estrogen has well known effects on striatal DA systems, however, most research 
has examined these effects after systemic administration of E, and therefore it is 
not clear whether E exerted its effects on NA directly (Becker, 1999; Lammers et 
al., 1999; Shieh and Yang, 2008). Note that a few studies have show that direct 
application of E to NA can potentiate DA activity (Lee and Mouradian, 1999; 
Thompson, 1999; Thompson and Certain, 2005; Thompson and Moss, 1994), 
132
and that direct application of E to NA can produce behavioral effects similar to 
those reported after DA agonist administration to NA (Roy et al., 1990; Schultz et 
al., 2009; Walf et al., 2007; Xiao and Becker, 1997). Additionally, while the 
presence of ERs in the NA are not well-defined (Shughrue et al., 1997), several 
studies have reported effects of E at ER receptors in NA (Phillips-Farfan et al., 
2007; Walf et al., 2007). Note that while multiple mechanisms by which E can 
potentiate DA in NA have been worked out, no one has investigated whether E 
exerts its effects at the level of the NA via the activation of increased AC-cAMP 
intracellular signaling cascades.  
 With respect to the proposal that E and DA operate through similar 
underlying mechanisms, the fact that E can produce effects on both gene 
transcription as well as modify existing protein activity via the induction of 
intracellular cell signaling cascades, suggests that it can produce cellular effects 
similar to DA D1 stimulation. In support of this idea, membrane-initiated effects of 
E can occur at ERα, ERβ, (Abraham et al., 2004; Razandi et al., 1999; Razandi 
et al., 2004) and at a novel G protein coupled receptor 30 (GPR30) which binds 
E (Filardo et al., 2007). The MPOA contains both isoforms of the ER (α and β; 
Shughrue et al., 1997), and GPR30 has also been localized to the MPOA 
(Canonaco et al., 2008). At the present time it is not clear whether NA expresses 
GPR30, however it has been recently been reported that GPR30 is expressed in 
the dorsal striatum (Hammond et al., 2009).
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 The results of study 2 indicate that the facilitatory effects of DA release in 
NA on the onset of maternal behavior in 15HO rats are mediated by DA D1 
receptors which are linked to the stimulatory G protein, Gs, which activates the 
enzyme AC and initiates cAMP intracellular signaling cascades. This finding is 
important for 2 reasons. (1) If systemic injection of E2 promotes the onset of 
maternal behavior in 15HO rats by acting, in part, at the level of the NA, it might 
produce facilitatory effects via membrane-initiated cAMP intracellular signaling 
cascades. For example, there is evidence that E2 stimulation, like SKF 83822, is 
capable of increasing cAMP intracellular signaling at both ERα (Abraham et al., 
2004; Aronica et al., 1994; Lagrange et al., 1997; Watters and Dorsa, 1998) as 
well as GPR30 (Filardo et al., 2007). (2) These findings also conform with our 
hypothesis that DA functions to inhibit NA projection neurons. 
Electrophysiological data, both in vivo and in vitro, suggest that the inhibitory 
effect of DA stimulation on NA medium spiny neurons is mediated by DA D1 
receptors (Calabresi et al., 1987; Charara and Grace, 2003; Chergui and Lacey, 
1999; Harvey and Lacey, 1996, 1997; Maeda et al., 2004; Nicola and Malenka, 
1997). Although it is not clear, at present, whether this D1 inhibition effect on 
medium spiny neurons is liked to the cAMP cascade, note that  downstream 
targets of cAMP signaling, such as cyclic AMP response element binding protein 
(CREB), have been shown to critically regulate the onset of sexual behavior in 
naive or socially isolated male rats (Barrot et al., 2005). This finding suggests a 
role for CREB activity in NA in the onset of reproductive behavior. 
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 Importantly, E can initiate PLC intracellular signaling cascades as well as 
cAMP intracellular signaling cascades (Kelly and Levin, 2001; Kow and Pfaff, 
2004; Razandi et al., 1999; Qui et al., 2003). While the specific DA D1 receptor 
subtype which mediates the facilitatory effect of DA D1 stimulation in MPOA on 
maternal behavior is not known, it might be interesting to explore the possibility 
that distinct intracellular signaling cascades mediate the facilitatory effects of DA 
D1 receptor stimulation at the level of the MPOA  and the NA.  Importantly, 
because our model predicts the cellular effects of DA D1 action at the level of 
MPOA function to potentiate MPOA projections to the VTA, but that DA D1 action 
at the level of the NA functions to depress NA projection neurons to the VP, it is 
possible that distinct intracellular mechanisms occur in these two regions 
(however, note that this proposal is also based on the assumption that DA D1 
receptors which effect maternal behavior are located on output neurons in both 
regions). In support of this idea, recall that E participates in NO formation. One 
mechanism by which E has been found to rapidly effect NO formation is via ER- 
initiated increases in intracellular Ca2+ released from intracellular Ca2+ stores 
(Stefano et al., 1999), an effect which can be mediated by PLC intracellular 
signaling cascades. E has also been found to activate membrane ER  which 
interact with the Gq protein- coupled metabotropic glutamate receptor 1 
(mGLUR1) in MPOA (Mermelstein, 2009), and the subsequent activation of PKC 
has been found to act on MPOA neurons to facilitate female sexual receptivity 
(Micevych, et al., 2009). Therefore a critical question which should be addressed 
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by future studies is whether or not the facilitatory effects of DA D1 receptor 
stimulation of MPOA on the onset of maternal behavior in 15HO rats are 
mediated by DA D1-PLC linked receptors. 
  In conclusion, the data presented here indicate that hypothalamic DA 
systems as well as mesolimbic DA systems are involved in the regulation of the 
onset of maternal motivation, and suggest the possibility that E regulates the 
increased maternal responsiveness of dams which occurs naturally at birth 
through a direct potentiation of one or both of these systems, or through action 
on similar intracellular signaling cascades at one or both of these regions.
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